| Excerpt | Reference |
|---|
| "Opiate abuse is often associated with benzodiazepine abuse." | ( Monotti, R, 1993) |
| "Opiate dependence is a brain-related medical disorder that can be effectively treated with significant benefits for the patient and society, and society must make a commitment to offer effective treatment for opiate dependence to all who need it." | ( , 1998) |
| "Opiate addiction is a serious problem that has now spread worldwide to all levels of society." | ( Mandal, TK, 1999) |
| "Opioid dependence is a chronic, relapsing disorder with important public health implications." | ( Bigelow, GE; Chutuape, MA; Johnson, RE; Stitzer, ML; Strain, EC; Walsh, SL, 2000) |
| "Opiate addiction is a chronic, relapsing disorder." | ( Kreek, MJ; Vocci, FJ, 2002) |
| "Opiate abuse is a risk factor for human immunodeficiency virus (HIV) infection." | ( Barr, MC; Henriksen, SJ; Huitron-Resendiz, S; Phillips, TR; Sanchez-Alavez, M, 2003) |
| "Opioid dependence is generally considered synonymous with heroin dependence or dependence on prescribed opioid analgesics." | ( Hulse, GK; Khong, E; Sim, MG, 2004) |
| "Opiate dependence is a major health and social issue in many countries." | ( Bond, C; Inkster, K; Ludbrook, A; Matheson, C; Simoens, S, 2005) |
| "Opiate dependence is a major threat to the public health and social security of China because of its devastating medical effects, its impact on risk for HIV/AIDS and criminal behaviors, low rates of recovery and high rates of relapse." | ( Cubells, JF; Tang, YL; Zhao, C; Zhao, D, 2006) |
| "Opioid dependence is a chronic and relapsing medical disorder with a well-established neurobiological basis." | ( Fiellin, DA; Friedland, GH; Gourevitch, MN, 2006) |
| "Untreated opioid dependence is a major obstacle to the successful treatment and prevention of human immunodeficiency virus (HIV) infection." | ( Altice, FL; Basu, S; Eldred, L; Smith-Rohrberg, D; Stancliff, S; Sullivan, LE, 2006) |
| "Prescription opioid dependence is increasing, but treatment outcomes with office-based buprenorphine/naloxone among these patients have not been described." | ( Barry, DT; Chawarski, MC; Fiellin, DA; Moore, BA; O'Connor, PG; Schottenfeld, RS; Sullivan, LE, 2007) |
| "Opioid misuse is rarely an overt clinical problem during end of life or acute pain treatment." | ( Ballantyne, JC, 2007) |
| "Opiate dependence is a result of adaptive changes in signal transduction networks in several brain regions." | ( Aghajanian, G; Chan, GC; LaPlant, Q; Liu, R; Nestler, EJ; Renthal, W; Storm, DR; Xiao, G; Zachariou, V, 2008) |
| "Opioid dependence is a complex medical condition affecting neurocognitive and physical functioning." | ( Bruce, RD; Schleifer, RA, 2008) |
| "Management of opioid dependence is associated with many challenges such as the misuse of prescribed treatment and lack of medication adherence that can affect the clinical outcome of the patient." | ( Jan, S; Kaur, AD; McQueen, A, 2008) |
| "Opioid abuse is common in Iran." | ( Afshari, R; Koushesh, HR, 2009) |
| "Opioid dependence is a chronic relapsing condition for which long-term opioid substitution treatment (OST) is effective." | ( Bell, J; Mammen, K, 2009) |
| "Prescription opioid abuse is a major public health problem in the United States." | ( Bertholf, R; Merlo, L; Paulian, G; Reisfield, G; Wilson, G, 2010) |
| "Failure in treating opioid dependence is costly to the patient, the employer, managed care organizations, and the overall health care system." | ( Ruetsch, C, 2010) |
| "Opioid dependence is a growing problem." | ( Biondi, L; Calabria, R; Fiore, A; Magnelli, F; Peluso, E; Rota, AG; Vonella, D, 2010) |
| "Opioid dependence is common in HIV clinics." | ( Barditch-Crovo, P; Chaudhry, A; Cook, K; Fiellin, DA; Finkelstein, R; Hsu, J; Keruly, JC; Lau, B; Lucas, GM; Moore, RD; Olsen, Y; Woodson, T, 2010) |
| "Opioid dependence is an increasing problem among adolescents and young adults, but in contrast to the standard in the adult population, adoption of pharmacotherapies has been slow." | ( Curran, E; Fishman, MJ; Garrett, S; Subramaniam, G; Winstanley, EL, 2010) |
| "Opioid dependence is one of the most severe drug dependencies." | ( Krupitsky, E; Woody, G; Zvartau, E, 2010) |
| "Opioid abuse is a devastating, costly, and growing problem in the United States, and one for which treatment can be complicated by barriers such as access to care and legal issues." | ( Bryson, EO; Gevirtz, C; Lipson, S, 2010) |
| "Opioid dependence is becoming a more common problem in the United States that gives rise to many negative health and social consequences for both individuals and society as a whole." | ( Benich, JJ, 2011) |
| "Opioid addiction is a chronic disease treatable in primary care settings with buprenorphine hydrochloride, but this treatment remains underused." | ( Alford, DP; Bergeron, A; Botticelli, M; Kretsch, N; LaBelle, CT; Samet, JH; Winter, M, 2011) |
| "Opiate addiction is associated with decision-making deficits and we previously showed that the extent of these impairments predicts aspects of treatment outcome." | ( Abou-Saleh, M; Checinski, K; Clark, L; Davis, P; King, M; Mehta, MA; Passetti, F; White, S, 2011) |
| "Opioid dependence is a chronic, relapsing disorder that deleteriously influences the health of those afflicted." | ( Aghevli, M; Goodman, F; Gordon, AJ; Kavanagh, G; Krumm, M; Liberto, J; Paidisetty, S; Ramgopal, R; Trafton, J, 2011) |
| "Opioid dependence is associated with low rates of treatment-seeking, poor adherence to treatment, frequent relapse, and major societal consequences." | ( Gastfriend, DR; Illeperuma, A; Krupitsky, E; Ling, W; Nunes, EV; Silverman, BL, 2011) |
| "Opioid abuse is common in the United States and is currently on the rise." | ( D'Orazio, JL; Fischel, JA, 2012) |
| "Initiation into prescription opioid misuse is an important public health concern since opioids are increasingly associated with drug dependence and fatal overdose." | ( Harocopos, A; Jackson Bloom, J; Lankenau, SE; Silva, K; Teti, M; Treese, M, 2012) |
| "Opiate addiction is associated with many adverse health and social harms, fatal overdose, infectious disease transmission, elevated health care costs, public disorder, and crime." | ( Bailey, J; Barh, D; Blum, K; Bowirrat, A; Braverman, ER; Chen, AL; Chen, TJ; Damle, U; Downs, BW; Femino, J; Fornari, F; Giordano, J; Kerner, M; Morse, S; Oscar-Berman, M; Rector, C; Simpatico, T, 2011) |
| "Suspected opioid addiction is managed with structured opioid therapy, methadone or buprenorphine treatment, or abstinence-based treatment." | ( Kahan, M; Mailis-Gagnon, A; Srivastava, A; Wilson, L, 2011) |
| "Opioid dependence is a significant public health problem associated with high risk for relapse if treatment is not ongoing." | ( Bisaga, A; Kosten, T; Nunes, EV; O'Connor, PG; Sigmon, SC; Woody, G, 2012) |
| "Opioid addiction is a chronic, recurrent brain disease that is characterised by compulsive drug seeking and a high rate of relapse even after long periods of abstinence." | ( Mattioli, L; Perfumi, M; Titomanlio, F, 2012) |
| "The prevalence of opioid abuse is increasing in North America." | ( Bridgman-Acker, K; Kelly, LE; Koren, G; Lauwers, A; Madadi, P; Rieder, MJ, 2012) |
| "Relapse of opiate dependence is a common occurrence after detoxification and introduction of opiate addicts in abstinence from opiates." | ( Jovanović, T; Lazarević, D; Nikolić, G, 2012) |
| "Opioid dependence is a chronic relapsing condition which requires comprehensive care; pharmacological agents form the mainstay of its long term treatment." | ( Benegal, V; Chand, P; Murthy, P; Viswanath, B, 2012) |
| "Opioid dependence is a chronic relapsing disorder that shows excess mortality and comorbidity with somatic and psychiatric disorders." | ( Soyka, M, 2012) |
| "Prescription opioid use disorders are the second most common drug use disorder behind only cannabis use disorders." | ( Blanco, C; Iza, M; Olfson, M; Rafful, C; Schwartz, RP; Wang, S, 2013) |
| "Prescription opioid dependence is a growing problem, but little research exists on its treatment, including patient characteristics that predict treatment outcome." | ( Dreifuss, JA; Fiellin, DA; Fitzmaurice, GM; Frost, K; Griffin, ML; Hatch-Maillette, M; Potter, JS; Selzer, J; Sonne, SC; Weiss, RD, 2013) |
| "Opioid dependence is growing at an alarming rate in the United States, and opioid dependent patients have substantial medical, as well as psychiatric, conditions that impact their ability to work." | ( Byrne, SA; Cherniack, MG; Petry, NM, 2013) |
| "Opioid dependence is a serious worldwide health problem." | ( Dong, H; Gong, Z; Su, R; Yan, H; Yan, L; Yong, Z; Yu, G; Zhou, P, 2013) |
| "Opioid addiction is prevalent in the United States." | ( Azadfard, M; Blondell, RD; Homish, GG; Nathan, G; Neumann, AM, 2013) |
| "Prescription opioid abuse is a significant public health concern that requires strategies to reduce its impact, including development of abuse deterrent formulations." | ( Chilcoat, HD; Coplan, P; DeVeaugh-Geiss, AM; Havens, JR; Leukefeld, CG, 2014) |
| "Opioid dependence is a major risk factor for HIV infection, however, the impact of buprenorphine/naloxone treatment on HIV risk behaviors among HIV-infected opioid-dependent patients is unknown." | ( Caffrey, S; Chantarat, T; Chaudhry, A; Edelman, EJ; Fiellin, DA; Fiellin, LE; O'Connor, PG; Weiss, L, 2014) |
| "Chronic pain and opioid addiction are 2 pressing public health problems, and prescribing clinicians often lack the skills necessary to manage these conditions." | ( Arora, S; Camarata, C; Comerci, GD; Dillow, J; Duhigg, D; Geppert, CM; Jenkusky, SM; Kalishman, S; Katzman, JG; Koshkin, E; Landen, M; Loring, L; Marr, L; Taylor, DE, 2014) |
| "Prescription opioid abuse is an increasing public health concern in the USA." | ( Chartoff, EH; LeSage, MG; Pentel, PR; Potter, DN; Pravetoni, M; Tally, L, 2014) |
| "Opioid dependence is a severe medical disorder with a high psychiatric and somatic comorbidity and mortality rate." | ( Soyka, M, 2015) |
| "Prescription opioid dependence is increasing and creates a significant public health burden, but primary care physicians lack evidence-based guidelines to decide between tapering doses followed by discontinuation of buprenorphine hydrochloride and naloxone hydrochloride therapy (hereinafter referred to as buprenorphine therapy) or ongoing maintenance therapy." | ( Barry, DT; Cutter, CJ; Fiellin, DA; Moore, BA; O'Connor, PG; Schottenfeld, RS, 2014) |
| "Opiate abuse is also pervasive and is repeatedly seen in death investigations." | ( Hansma, P; Hlavaty, L; Sung, L, 2015) |
| "While opioid dependence is a complex health condition, the treatment of HIV-infected individuals with opioid dependence presents additional challenges." | ( Abood, ME; Benamar, K; Palma, J, 2015) |
| "Opioid use disorders are a significant public health problem, affecting two million people in the United States." | ( Burns, RM; Dick, AW; Gordon, AJ; Leslie, D; Pacula, RL; Sorbero, M; Stein, BD, 2015) |
| "Prescription opioid abuse is at epidemic levels." | ( Gilson, AM; Manworren, RC, 2015) |
| "Opioid addiction is no longer a primarily urban problem." | ( Meyer, M; Phillips, J, 2015) |
| "Prescription opioid abuse is associated with substantial economic burden, with estimates of incremental annual per-patient health care costs of diagnosed opioid abuse exceeding $10,000 in prior literature." | ( Ben-Joseph, R; Birnbaum, HG; Bodnar, K; Enloe, CJ; Holly, P; Kirson, NY; Rice, JB; Shei, A, 2015) |
| "Opioid use disorders are considered a serious public health problem among young adults." | ( DiGirolamo, G; Gonzalez, G; Kolodziej, M; Romero-Gonzalez, M; Smelson, D; Ziedonis, D, 2015) |
| "Opioid dependence is associated with high levels of morbidity, yet sparse data exists regarding the health-related quality of life (HRQoL) of individuals with opioid dependence, particularly following treatment initiation." | ( Aden, B; Ang, A; Bray, JW; Eggman, AA; Hser, YI; Ling, W; Nosyk, B; Potter, J; Schackman, BR; Weiss, RD; Wittenberg, E, 2015) |
| "Opioid abuse is a healthcare and societal problem that burdens individuals, their families and the healthcare professionals who care for them." | ( Brennan, MJ; Gudin, JA; Kwong, LM; Levandowski, R; Webster, LR, 2016) |
| "Prescription opioid misuse is a major public health concern in the United States, yet little is known about national prescription patterns." | ( Gebert, JT; Groenewald, CB; Palermo, TM; Rabbitts, JA, 2016) |
| "Opioid use disorders are common, chronic relapsing disorders." | ( Kumari, S; Lawson, WB; Leong, S; Malik, M; Manalai, P; Wooditch, A, 2016) |
| "Alcohol and opioid use disorders are common among adults under community supervision." | ( Friedmann, PD; Gordon, MS; James, A; Mitchell, SG; Monico, LB; Rudes, DS; Schwartz, RP; Viglione, J; Willet, J, 2016) |
| "If and when opioid misuse is detected, opioids do not necessarily need to be discontinued, but misuse should be noted on the problem list and interventions should be performed to change the patient's behavior." | ( Humphreys, K; Lembke, A; Newmark, J, 2016) |
| "Opioid abuse is a serious public health concern." | ( Cepeda, MS; Coplan, PM; Kopper, NW; Maziere, JY; Wallace, LE; Wedin, GP, 2017) |
| "Opioid use disorder is associated with significant health and social harms." | ( Ahamad, K; Fairgrieve, C; Joe, R; Voon, P, 2016) |
| "Opioid use disorder is a leading cause of morbidity and mortality among US youth." | ( , 2016) |
| "Opioid misuse is a growing public health problem, and estimates show a 150% increase in opioid-related hospital stays over the last two decades." | ( Ali, MM; Hughey, L; Mark, T; Mutter, R; Naeger, S, 2016) |
| "Although opioid abuse is a rising epidemic in the USA, there are no studies to date on the incidence of persistent opioid use following injuries." | ( Alghnam, S; Castillo, R, 2017) |
| "Opioid dependence is an increasing public health problem." | ( Aldemir, E; Coskunol, H; Kilic, M; Sert, I, 2016) |
| "Patients with opioid dependence are likely to experience specific barriers to accessing opioids in addition to those experienced by other non-dependent patients." | ( Jünger, S; Lisman, JA; Mantel-Teeuwisse, AK; Radbruch, L; Scholten, W; Schutjens, MDB; Subataite, M; Vranken, MJM, 2017) |
| "Concomitant opioid misuse is an increasing problem in opioid maintenance treatment as it interferes with treatment success." | ( Adam, R; Al-Iassin, J; Canolli, M; Koller, G; Krause, D; Martin, G; Musselmann, R; Plörer, D; Pogarell, O; Schäfer, F; Walcher, S; Winter, C, 2017) |
| "Opiate addiction is associated with complex cognitive impairment, which contributes to the development of compulsive drug use and relapses." | ( Guo, H; Lai, J; Wang, Y; Yan, P; Yin, F; Zhang, J, 2017) |
| "Chronic pain and prescription opioid abuse are extremely prevalent both in this country and worldwide." | ( Beakley, BD; Bolden, JL; Calixto, F; Galan, V; Jones, MR; Kaye, AD; Kaye, AM; Manchikanti, L; Ripoll, JG; Urman, RD, 2017) |
| "Chronic pain and prescription opioid abuse are extremely prevalent in the United States and worldwide." | ( Beakley, BD; Bolden, JL; Calixto, F; Galan, V; Jones, DE; Jones, MR; Kaye, AD; Kaye, AM; Manchikanti, L; Ripoll, JG; Urman, RD, 2017) |
| "Opioid dependence is a chronic condition with substantial health, economic and social costs." | ( Chetty, M; Dunlop, WC; Kenworthy, JJ; Langham, S; Walker, A, 2017) |
| "Opioid abuse is also costly: previous estimates of the annual excess costs of opioid abuse to payers range from approximately $10,000 to $20,000 per patient." | ( Birnbaum, HG; Dincer, AP; Enloe, CJ; Kirson, NY; Mayne, TJ; Scarpati, LM, 2017) |
| "Opioid use disorder is often treated with short term hospitalization and medically supervised withdrawal from opioids followed by counseling alone without medication assisted treatment (MAT)." | ( Boney, TY; Chen, DT; Fishman, MJ; Friedmann, PD; Gordon, M; Hu, MC; Lee, JD; Nunes, EV; O'Brien, CP; Wilson, D, 2018) |
| "Opioid use disorder is common in prison populations, and prison release is a high-risk time for relapse and overdose." | ( Clarke, JG; Friedmann, PD; Hoskinson, R; Poshkus, M; Wilson, D, 2018) |
| "Opioid use disorder is a chronic, relapsing disease that encompasses use of both prescription opioids and heroin and is associated with a high annual rate of overdose deaths." | ( Chavoustie, S; Dammerman, R; Darwish, M; Frost, M; Owen, J; Sanjurjo, V; Snyder, O, 2017) |
| "Prescription opioid misuse is a rising epidemic in the U." | ( Bullock, D; Flores, J; Ketchum, NS; Liang, Y; Potter, JS; Taylor, BS; Turner, BJ; Villarreal, R, 2018) |
| "Opioid dependence is associated with high morbidity and mortality." | ( Caritis, SN; Kalluri, HV; Venkataramanan, R; Zhang, H, 2017) |
| "Opioid use disorder is a serious public health problem." | ( Andrilla, CHA; Coulthard, C; Larson, EH, 2017) |
| "Opioid use disorder is a growing epidemic, with an alarming number of associated deaths." | ( Chopra, N; Marasa, LH, 2017) |
| "Opioid abuse is a major problem around the world." | ( Bardo, MT; Beckmann, JS; Chow, JJ; Hofford, RS, 2017) |
| "Opioid addiction is a public health crisis that affects all areas of medicine." | ( Carr, NJ; Clarke, H; Demsey, D; Vipler, S, 2017) |
| "Prescription opioid abuse is a growing concern that has garnered widespread attention among policymakers and the general public." | ( Patel, S; Sternberg, P, 2017) |
| "Opioid abuse is a growing problem in civilian communities, and it has developed in the military as well." | ( Bebarta, VS; Borys, DJ; Maddry, JK; Ng, PC; Sessions, D, 2017) |
| "Perinatal opioid misuse is a complex, multifaceted problem that demands a multidisciplinary cross specialty approach." | ( Davis, JM; Devlin, LA, 2018) |
| "Chronic opioid misuse is associated with reduced sensitivity to natural rewards and social motivation deficits that include impaired caregiving." | ( Bouril, A; Elman, I; Fairchild, VP; Gur, RC; Langleben, DD; Lowen, SB; Shi, Z; Wang, AL, 2018) |
| "While prescription opioid abuse is part of the opioid problem, it is by no means the entirety of it." | ( LeQuang, JA; Pergolizzi, JV; Raffa, RB; Taylor, R, 2018) |
| "Opioid abuse is a common disorder affecting over 2 million Americans." | ( Chowdhury, NI; DelGaudio, JM; Levy, JM; Morrison, DA; Wise, SK, 2018) |
| "Intranasal opioid abuse is a prevalent condition associated with chronic pain and tissue necrosis that is clinically concerning for invasive fungal disease." | ( Chowdhury, NI; DelGaudio, JM; Levy, JM; Morrison, DA; Wise, SK, 2018) |
| "Opioid addiction is a chronic, relapsing disorder associated with criminality, unemployment, infectious diseases, and legal problems." | ( Chaplin, MM; Farahmand, P; Modesto-Lowe, V, 2017) |
| "Twin studies of opioid addiction are consistent with an inherited component of risk, approximately 50%." | ( Berrettini, W, 2017) |
| "Opioid addiction is a serious public health concern with severe health and social implications; therefore, extensive therapeutic efforts are required to keep users drug free." | ( Baijnath, S; Gopal, ND; Govender, T; Kruger, HG; Naicker, T; Pamreddy, A; Teklezgi, BG, 2019) |
| "Prescription opioid misuse is highly prevalent among PLWHA and can lead to a variety of adverse outcomes." | ( Chilcott, LN; Ditre, JW; Flood, K; LaRowe, LR; Vanable, PA; Zvolensky, MJ, 2018) |
| "Opioid misuse is regularly associated with disrupted functioning in those with chronic pain." | ( Bailey, RW; Bolling, L; Edwards, KA; McEntee, ML; Pielech, M; Sullivan, MD; Vowles, KE; Witkiewitz, K, 2018) |
| "Opioid use disorder is a serious public health burden, especially throughout rural America." | ( Andrilla, CHA; Coulthard, C; Patterson, DG, 2018) |
| "Opioid abuse is a major risk factor for HIV infection." | ( Berman, JW; Jaureguiberry-Bravo, M; Lopez, L, 2018) |
| "Prior opioid dependence is associated with increased risk and increasing age is associated with decreased risk of opioid dependence following surgery for DS." | ( Aljuboori, Z; Boakye, M; Drazin, D; Nuño, MA; Sharma, M; Ugiliweneza, B, 2018) |
| "Opioid dependence is a chronic mental disease with multifactorial etiology." | ( Bonnet, U; Scherbaum, N, 2018) |
| "Risk for opioid misuse is a crucial consideration for patients with chronic pain, given the recent high rates of opioid-related deaths in the U." | ( Gross, RT; Lutz, J; Vargovich, AM, 2018) |
| "Opioid addiction is a major public health issue worldwide." | ( Chen, HJ; Huang, CL; Hung, CC; Lee, HY; Lee, TE; Wang, JY; Wang, RY, 2018) |
| "Prescription opioid misuse is a serious public health concern, yet antecedent factors are poorly described." | ( Beals-Erickson, SE; Fisher, E; Groenewald, CB; Law, EF; Palermo, TM, 2019) |
| "Opioid misuse is a growing crisis." | ( Arthur, JA; Bruera, E; Edwards, T; Kuriakose, L; Liu, D; Lu, Z; Manju, J; Najera, J; Nguyen, K; Reddy, SK; Williams, JL; Wu, J; Yennurajalingam, S, 2018) |
| "Considering that opioid use disorder is a chronic condition, efforts need to be made to target factors associated with retention." | ( Amiri, S; Amram, O; Hirchak, K; Lutz, R; McDonell, MG; McPherson, SM; Roll, JM, 2018) |
| "Prescription opioid abuse is now an epidemic that has forced the government and industries to take initiatives." | ( Ahmad, R; Alaei, S; Omidian, H, 2018) |
| "Opioid use disorder is one of the most prevalent addiction problems worldwide." | ( Ahmadi, J; Ghahremani, D; Jahromi, MS; London, ED, 2018) |
| "Opioid use disorder is a growing social problem." | ( Alban, K; Baykara, S, 2019) |
| "Opioid dependence is a significant public health problem in the United States and the number of opioid overdose deaths among women has increased dramatically in comparison to men in the last few years." | ( Back, SE; Baker, NL; Brady, KT; Davis, CM; Gilmore, AK; Guille, C; Hahn, CK; McCauley, JL, 2019) |
| "Opioid abuse is now the most common cause of accidental death in the US." | ( Alazizi, A; Bannon, MJ; Guerra, MH; Jaster, AM; Luca, F; Olson, PD; Pique-Regi, R; Rumschlag, M; Saad, MH; Savonen, CL; Schmidt, CJ, 2019) |
| "Opioid use disorder is a major health concern in North America." | ( Cleverley, K; Ling, S; Mangaoil, R; Puts, M; Sproule, B, 2019) |
| "Opioid dependence is a chronic mental disease with multifactorial etiology." | ( Bonnet, U; Scherbaum, N, 2019) |
| "Women with opioid use disorder are at increased risk of other medical complications of pregnancy." | ( Jones, M; Prasad, M, 2019) |
| "Opioid use disorder is characterised by the persistent use of opioids despite the adverse consequences of its use." | ( Blanco, C; Volkow, ND, 2019) |
| "Opioid misuse is a national epidemic, and Ohio is one of the states most impacted by this crisis." | ( Bonny, A; Hepler, S; Kline, D; McKnight, E, 2019) |
| "Opioid use disorder is a chronic, debilitating, and costly disorder that has increased in prevalence in many countries, with an associated sharp rise in mortality." | ( Byford, S; Hellier, J; James, K; Kelleher, M; Kelly, J; Marsden, J; Mitcheson, L; Murphy, C; Shearer, J; Stillwell, G, 2019) |
| "Opioid abuse is a significant public health problem in the United States." | ( Agboola, F; Banken, R; Chapman, RH; Kumar, VM; Ollendorf, DA; Segel, C; Synnott, PG; Webb, M, 2019) |
| "Opioid misuse is a national health crisis that requires sustained treatment, prevention, and recovery efforts." | ( Clarke, T; High, PM; Manocchio, T; Marks, K; Robbins, V; Stringer, M; Winograd, R; Wood, C, 2020) |
| "Opioid abuse is strongly associated with early post-discharge mortality." | ( Becker, EA; Maughan, BC, 2019) |
| "Opioid use disorder is highly prevalent and can be fatal." | ( Coffa, D; Snyder, H, 2019) |
| "Reported prescription opioid misuse is common among adolescents and young adults and often associated with additional substance abuse, underscoring the importance of drug and alcohol screening programs in this population." | ( Bourgeois, FT; Hudgins, JD; Monuteaux, MC; Porter, JJ, 2019) |
| "Opioid abuse is an epidemic in the United States and trauma can initiate persistent use; however, it remains unclear whether persistent opioid use contributes to the subsequent development of opioid abuse." | ( Beyer, CA; Dunham, JR; Gundlapalli, A; Howard, JT; Janak, JC; Kazanis, WH; Pettey, W; Poltavskiy, E; Redd, A; Rittel, AG; Rutter, WC; Sim, A; Stewart, IJ; Suo, Y; Walker, LE; Watrous, JR; Zarzabal, LA, 2021) |
| "Opioid use disorder is a major public health crisis." | ( Carroll, KM; Lichenstein, SD; Potenza, MN; Scheinost, D; Yip, SW, 2021) |
| "Opioid addiction is a public health concern." | ( Brenes, F; Henriquez, F, 2020) |
| "Opioid use disorder is common among detainees in US jails, yet methadone treatment is rarely initiated." | ( Jaffe, JH; Kelly, SM; Mitchell, SG; O'Grady, KE; Schwartz, RP; Sharma, A, 2020) |
| "Opioid addiction is a major public health threat to healthy life expectancy; however, little is known of long-term mortality for mothers with opioid use in pregnancy." | ( Amartey, A; Blackburn, R; Chiu, M; Gilbert, R; Guttmann, A; Harron, K; Saunders, N; Wijlaars, L; Zhou, L, 2019) |
| "Opioid abuse is a public health crisis." | ( Ortman, HA; Siegel, JA, 2020) |
| "Human prescription opioid abuse is marked by chronic, voluntary, oral intake and sex differences." | ( Barr, GA; DeSalle, MJ; Deutsch, HM; Eisch, AJ; Zanni, G, 2020) |
| "Opioid use disorder is a chronic relapsing disease and treatment models that retain patients long-term have the greatest benefit." | ( Berry, JH; Hustead, JD; Lander, LR; Mahoney, JJ; Marshalek, P; Winstanley, EL; Zheng, W, 2020) |
| "Opioid use disorder is increasingly common in the United States and affects many pregnancies." | ( Bouchard, L; Cheng, C; Zhao, L, 2020) |
| "Opioid use disorder is a common, chronic condition with significant implications during pregnancy." | ( Bouchard, L; Cheng, C; Zhao, L, 2020) |
| "Opioid addiction is recognized as a chronic relapsing brain disease resulting from repeated exposure to opioid drugs." | ( Cechova, K; Jagr, M; Roubalova, L; Svoboda, P; Ujcikova, H; Vosahlikova, M, 2020) |
| "Adolescents with opioid use disorder are less likely than adults to receive medications for opioid use disorder (MOUD), yet we know little about facilities that provide addiction treatment for adolescents." | ( Alinsky, RH; Cerda, M; Hadland, SE; Matson, PA; Saloner, B, 2020) |
| "People with opioid use disorder are prevalent in criminal problem-solving courts and dependency courts, which have rehabilitative aims." | ( Andraka-Christou, B; Atkins, D; Madeira, J; Silverman, RD, 2020) |
| "Opioid dependence is a severe disease which is associated with a high risk of relapse, even in cases of successful withdrawal therapy." | ( Bleich, S; Dürsteler-MacFarland, KM; Frieling, H; Groeschl, M; Groh, A; Heberlein, A; Hillemacher, T; Jahn, K; Janke, E; Kornhuber, J; Lenz, B; Lichtinghagen, R; Mühle, C; Wiesbeck, GA, 2021) |
| "Opiate addiction is increasing and plaguing the western world and specifically the U." | ( Berger, AA; Hasoon, J; Jung, JW; Kassem, H; Kaye, AD; Mousa, M; Patel, A; Urits, I; Virgen, CG; Viswanath, O; Zusman, R, 2020) |
| "Opioid use disorder is complex and not easily quantified among US populations because there are no dedicated reporting systems in place." | ( Bradley, HM; Rio, CD; Rosenberg, ES; Sullivan, PS, 2020) |
| "Prescription opioid misuse is a risk factor for opioid use disorder (OUD)." | ( Shen, C; Thornton, D; Varisco, T, 2020) |
| "Opioid abuse is a significant cause of morbidity and mortality in the United States, and injection drug use (IDU) is a common form of opioid abuse." | ( Coyle, RO; Jatis, AJ; Karlan, NM; Miller, AC; Polgreen, LA; Stafford, SR, 2021) |
| "Opioid use disorder is a major public health crisis, and evidence suggests ways of better serving patients who live with opioid use disorder in the emergency department (ED)." | ( Biggs, C; Deol, J; Dong, K; Fanaeian, J; Fielding, S; Fisher, A; Ghosh, SM; Hair, H; Holroyd, BR; Lang, E; McLane, P; Olmstead, A; Ross, M; Scott, K; Suleman, Z; Tanguay, R; Yee, K, 2020) |
| "Prescription opioid misuse is an ongoing crisis and a risk factor for injection drug use (IDU)." | ( Earlywine, JJ; Hadland, SE; Raifman, J, 2020) |
| "Opioid use disorders are chronic and relapse is common." | ( Bunce, SC; Cleveland, HH; Cleveland, MJ; Jenkins, GJ; Knapp, KS, 2021) |
| "Patients with opioid use disorder are over-represented in ED presentations." | ( Cantwell, K; Dietze, P; Higgs, P; Hutton, J; Lloyd-Jones, M; Salter, H; Straub, A; Zordan, R, 2020) |
| "Prescription opioid misuse is a major public health concern among children and adolescents in the United States." | ( Blendy, JA; Carpenter, MD; Heller, EA; Manners, MT, 2021) |
| "Opioid use disorder is a critical public health problem that continues to broaden in scope, adversely affecting millions of people worldwide." | ( Baumann, MR; Strout, TD; Wendell, LT, 2021) |
| "Opioid addiction is characterized by compulsive drug seeking and taking behavior, which is thought to result from persistent neuroadaptations." | ( Eckhardt, A; Hejnova, L; Novotny, J; Roubalova, L; Svoboda, P; Ujcikova, H, 2021) |
| "Opiate addiction is a major health challenge with substantial societal cost." | ( Fonville, L; Hayes, A; Herlinger, K; Hill, R; Lingford-Hughes, A; Nutt, D; Paterson, L, 2021) |
| "Opioid dependence is a public health crisis and surgery is a risk factor for long-term opioid use." | ( Bastawrous, AL; Brockhaus, KK; Chang, MI; Cleary, RK; Li, Y; Milky, G; Shih, IF, 2022) |
| "Opioid abuse is a chronic disorder likely involving stable neuroplastic modifications." | ( Gades, MS; Gewirtz, JC; Harris, AC; Liu, SX; Ramakrishnan, A; Swain, Y; Tran, PV, 2021) |
| "Opioid use disorder is associated with feelings of social isolation, an increased risk of suicide and, at the community level, lower social capital." | ( Christie, NC, 2021) |
| "Prescription opioid misuse is a significantly greater risk factor for gun and other weapon carrying among male US high school students, which disproportionately increases the risk for violence perpetration, including suicide among these students." | ( Pontes, M; Pontes, NMH, 2021) |
| "Opioid abuse is an increasingly global phenomenon." | ( Singh, B, 2021) |
| "Prescription opioid misuse is more common among the black population." | ( Goudra, B; Guthal, A; Singh, PM, 2021) |
| "Opioid misuse is now considered a major public health epidemic in North America, with substantial social and financial consequences." | ( Adiamah, A; Daliya, P; Knaggs, RD; Levy, N; Lobo, DN; Roslan, F; Theophilidou, E, 2021) |
| "Opioid use disorder is a growing concern in the United States." | ( Beardsley, PM; Carper, M; Contreras, KM; Damaj, MI; Walentiny, DM, 2021) |
| "Opioid use disorder is a serious health condition for which buprenorphine is proven effective, yet providers substantially underutilize buprenorphine." | ( Banta-Green, CJ; Hansen, RN; Merrill, JO; Ossiander, EM; Wasserman, CR, 2021) |
| "Opioid use disorder is a worldwide societal problem and public health burden." | ( Cao, DN; Li, F; Li, J; Wu, N, 2023) |
| "Opioid use disorders are serious contributors to the harms associated with the drug use." | ( Daniel, WA; Filip, M; Frankowska, M; Jastrzębska, J; Kleczkowska, P; Pieniążek, R; Pukło, R; Suder, A; Surówka, P; Zadrożny-Bujalska, M, 2021) |
| "Opioid abuse is a public health crisis and the perioperative period can be a time of first opioid exposure." | ( Andersen, P; Cetas, J; Detwiller, KY; Dogan, A; Farrell, NF; Geltzeiler, M; Gupta, S; Mace, JC; Pailet, J; Rimmer, RA; Scott, B; Smith, TL, 2022) |
| "Opioid misuse is a widespread public health problem, and opioids are often prescribed in the dental environment." | ( Cotchery, DL; Farooqi, OA; Ferguson, DK; Foran, D; Gibson, G; Hakki, OW; Panchal, NH; Silva, R; Smith, GM; Wehler, CJ, 2021) |
| "The diagnosis of opioid use disorder is not the same as the diagnosis of substance dependence according to ICD-10, as the DSM‑5 diagnosis covers a much broader spectrum (mild, moderate, severe)." | ( Häuser, W; Just, J; Petzke, F; Radbruch, L; Scherbaum, N; Weckbecker, K, 2022) |
| "Opioid use disorder is a major public health problem, and opioid replacement therapy with buprenorphine (BPN) is a clinically effective and evidence-based treatment for it." | ( Balhara, YPS; Modak, T; Sarkar, S, 2021) |
| "Pharmacotherapy for opioid use disorder is effective but underused from a clinical perspective, and average treatment duration is shorter than current recommendations." | ( McPheeters, J; Mutter, R; Spencer, D, 2022) |
| "Opioid abuse is a worldwide public health issue, and deaths related to opioid abuse are increasing." | ( Aronow, WS; Briasoulis, A; Malik, SS, 2022) |
| "Opioid use disorder is used as an exemplar for substance use disorders and clinical recommendations are included with expanded attention to risk assessment and mitigation with interventions targeted to minimize the risk for relapse or escalation of substance use." | ( Compton, P; Matteliano, D; Oliver, J; Sowicz, TJ; St Marie, B; Strobbe, S; Turner, HN; Wilson, M, 2022) |
| "Opioid use disorder is a public health problem and treatment variability, coverage and accessibility poses some challenges." | ( Puig, T; Samsó Jofra, L; Solà, I; Trujols, J, 2022) |
| "Opiate addiction is common among offenders, and many opiate-dependent lawbreakers are treated in the correctional system according to § 64 STGB." | ( Soyka, M; Steinböck, H, 2022) |
| "However, opioid misuse is widespread, and cancer patients are at risk." | ( Keall, P; Keall, R; Kiani, C; Lovell, M; Luckett, T; McNeill, R, 2022) |
| "Opioid misuse is common, as is opioid agonist treatment of opioid dependence." | ( Demirkol, A; Murnion, BP, 2022) |
| "Opioid use disorder is a significant global issue and the rate of opioid use in women of childbearing age and pregnant women is on the rise." | ( Baldacchino, A; Conti, AA; Hemmati, Z, 2022) |
| "Opioid use disorder is a highly heterogeneous disease driven by a variety of genetic and environmental risk factors which have yet to be fully elucidated." | ( Akbarian, S; Bartels, CF; Ben Hutta, G; Cates, H; Corradin, O; Cuoto, L; Gryder, BE; Hancock, DB; Hays, C; Hoang, AT; Iskhakova, M; Johnson, EO; Kassim, BS; Lovrenert, K; Mash, DC; Quach, BC; Sallari, R; Scacheri, PC; Song, Y, 2022) |
| "Opioid misuse is hypothesized to compromise the ability to regulate negative emotions, as manifested through visceral and peripheral physiological signals." | ( Bernat, EM; Fix, ST; Froeliger, B; Garland, EL; Hudak, J; Prince, KC, 2022) |
| "Opioid dependence is an important public health issue with high rates of relapse." | ( Andrada, E; Bandalan, JH; Dangelo-Kemp, D; Johnston, L; Rodriguez, M; Wilson, H, 2022) |
| "Medication for opioid use disorder is the evidence-based, standard of care for treating OUD in outpatient settings, especially buprenorphine because it is effective and has low toxicity." | ( Aspero, H; Bao, Y; Bogner, HR; Calderbank, T; Campbell, K; Coviello, D; Dooley, P; French, R; Harris, RA; Lowenstein, M; Maginnis, J; Mandell, DS; O'Donnell, N, 2022) |
| "Prescription opioid misuse is an ongoing epidemic in the United States." | ( Fields, KG; Kaye, AD; Thomas, AT; Urman, RD, 2022) |
| "Opioid misuse is a critical public health crisis in the United States that results in over 50,000 deaths per year and a substantial economic burden to society." | ( Cavigelli, SA; Flarend, G; Horton, WJ; Kamens, HM; Wickenheisser, A, 2023) |
| "Opioid misuse is a nationwide public health crisis." | ( Bonifonte, A; Garcia, E, 2022) |
| "Medications for opioid use disorder are an effective, life-saving treatment, but patients with an opioid use disorder admitted to the hospital seldom initiate medication for their disorder while in the hospital, nor are they linked with outpatient treatment after discharge." | ( Chan Osilla, K; Danovitch, I; Friedmann, PD; Huerta, S; Leamon, I; Mazer, MW; Messineo, G; Murray-Krezan, C; Nuckols, T; Ober, AJ; Page, K; Ryzewicz, S; Watkins, KE, 2022) |
| "Opioid dependence is causing an epidemic in the US, but unlike the 1970s it seems more related to prescription opioids than heroin." | ( Hernández Julián, I; López-Vílchez, MÁ; Medina Martí, P; Mur Sierra, A, 2023) |
| "Opioid use disorder is a chronic brain disease influenced by genetic and epigenetic factors, accounting for approximately 50% of the liability." | ( Cheng, C; Fu, X; Lu, Y; Wang, K; Xie, Q; Zhang, J; Zhu, Y, 2022) |
| "As a result, opioid misuse is a cause for concern and is considered an epidemic." | ( Bednarova, R; Biancuzzi, H; Brescia, V; Campostrini, S; Cascella, M; Cobianchi, L; Cuomo, A; Dal Mas, F; Dorken-Gallastegi, A; Gebran, A; Kaafarani, HM; Marinangeli, F; Massaro, M; Miceli, L; Renne, A; Scaioli, G; Vittori, A, 2022) |
| "Opioid use disorder is associated with high rates of mortality and has become an escalating global health issue." | ( Danø, A; Gibbons, C; Jensen, R; Pedersen, MH, 2022) |
| "Opioid misuse is strongly associated with suicidal behaviors among veterans." | ( Betancourt, CA; Goldberg, DG; Hawks, BA; Kitsantas, P, 2023) |
| "People with opioid use disorder are less likely than others to have a primary care physician." | ( Hum, S; Kiran, T; Meaney, C; Mogic, L; Moineddin, R; Spithoff, S, 2022) |
| "Opioid use disorders are associated with a high burden of disease and treatment gap." | ( Chiliza, B; Kiburi, SK; Ngarachu, E; Paruk, S; Tomita, A, 2023) |
| "Opioid use disorders are commonly treated by long-acting agonist opioids including methadone and buprenorphine which could affect various aspects of male reproduction especially spermatogenesis." | ( Abedini, M; Amirinejad, M; Haghpanah, T; Moinaddini, F; Nematollahi-Mahani, SN; Yoosefi, F, 2023) |
| "Opioid use disorders are commonly treated by long-acting agonist opioids including methadone and buprenorphine which could affect various aspects of male reproduction especially spermatogenesis." | ( Abedini, M; Amirinejad, M; Haghpanah, T; Moinaddini, F; Nematollahi-Mahani, SN; Yoosefi, F, 2023) |
| "Opioid use disorders are commonly treated by long-acting agonist opioids including methadone and buprenorphine which could affect various aspects of male reproduction especially spermatogenesis." | ( Abedini, M; Amirinejad, M; Haghpanah, T; Moinaddini, F; Nematollahi-Mahani, SN; Yoosefi, F, 2023) |
| "In the USA, opioid use disorder care is maximally disruptive." | ( Englander, H; Gregg, J; Levander, XA, 2023) |
| "In the USA, opioid use disorder care is maximally disruptive." | ( Englander, H; Gregg, J; Levander, XA, 2023) |
| "In the USA, opioid use disorder care is maximally disruptive." | ( Englander, H; Gregg, J; Levander, XA, 2023) |
| "Opioid use disorder is a serious public health problem in Nepal." | ( Howard, J; Lien, L; Ojha, SP; Pant, SB; Thapa, SB, 2023) |
| "Opioid addiction is a major public health issue, yet its underlying mechanism is still unknown." | ( Chen, Z; Dong, B; Hou, X; Jia, J; Li, G; Li, Y; Liang, J; Lu, Y; Wang, Y; Wei, S; Yan, J; Zhang, M; Zhang, Q; Zhang, Y; Zheng, T, 2023) |
| "Opioid use disorder is a public health concern in Australia." | ( Abimanyi-Ochom, J; Hall, NY; Le, L; Mihalopoulos, C; Teesson, M, 2023) |
| "Medications for opioid use disorder are effective at reducing risk of fatal overdose but are underutilized, as is the opioid reversal medication naloxone." | ( Bell, LA; Hadland, SE, 2023) |
| "Opioid misuse is a growing public health concern in the United States (U." | ( Kyei, EF; Leveille, S, 2023) |
| "Opioid addiction is characterized by adaptations in the mesolimbic dopamine system that occur during chronic opioid use." | ( Dursun, SM; Nickols, JER; Taylor, AMW, 2023) |
| "Opioid dependence is associated with substantial health and social burdens, and opioid agonist treatment (OAT) is highly effective in improving multiple outcomes for people who receive this treatment." | ( Clark, B; Degenhardt, L; Farrell, M; Hickman, M; Kimber, J; Larance, B; Leppan, O; Macpherson, G; Martino-Burke, D; Nielsen, S; Zahra, E, 2023) |
| "Opioid use disorder is a major public health concern that accounts for a high number of potential years of life lost." | ( Day, N; Deol, J; Dong, K; Fanaeian, J; Faris, P; Ghosh, M; Holroyd, BR; Lang, E; Low, K; McLane, P; Ross, M; Scott, K; Stone, KD; Taghizadeh, N; Tanguay, R; Yee, K, 2023) |
| "Opioid misuse is a nationwide issue and is of particular concern with regard to military readiness." | ( Janvrin, ML; Koehlmoos, TP; Korona-Bailey, J; Madsen, C; Schoenfeld, AJ, 2023) |
| "Opioid use disorder is a public health crisis that causes tremendous suffering for patients as well as substantial social and economic costs for society." | ( Hofford, RS; Kiraly, DD; Sens, JP, 2023) |
| "Opioid addiction is a serious public health problem in the US, and this study aimed to explore how natural language processing (NLP) can be used to identify factors that contribute to distress in individuals with opioid addiction, and then use this information along with structured data to predict the outcome of opioid treatment programs (OTP)." | ( Cui, W; Finkelstein, J; Shah-Mohammadi, F, 2023) |
| "Opioid abuse is one of the most obvious problems in today's world and directly affects individuals' quality of life." | ( Hosseini, SA; Musarezaie, A; Rezazadeh, M, 2023) |
| "Opioid use disorder is a leading cause of death through the year postpartum." | ( Britton, E; Cunningham, P; Johnson, J; Martin, CE; Sabo, R; Shadowen, H, 2023) |
| Excerpt | Reference |
|---|
| "New medications for the treatment of opiate dependence are being developed." | ( Ling, W; Wesson, DR, 1990) |
| "A questionnaire concerning knowledge of opiate abuse and attitudes about abusers was administered to 94 randomly selected physicians and medical students at a large urban teaching hospital." | ( Demas, P; Shine, D, 1984) |
| "Naloxone tests for opiate dependence were given to 296 applicants for treatment with the surrogate opiate levomethadyl acetate (LAAM, levo-alpha-acetylmethadol) and to 103 applicants for treatment with the opiate antagonist naltrexone." | ( Goldstein, A; Himmelberger, DU; Judson, BA, 1980) |
| "Two groups of subjects, opioid abusers (n = 20) and nonabusers (n = 20), received either one 15 mg/70 kg IM morphine pretreatment or two such pretreatments spaced 24 h apart." | ( Azolosa, JL; Greenwald, MK; Stitzer, ML, 1994) |
| "Methadone treatment for opioid dependence needs to be promoted and liberalized, especially because the oral route of administration eliminates the risks accompanying drug injection." | ( Blansfield, HN, 1996) |
| "Methadone maintenance for the treatment of opioid dependence is described in this article." | ( Berghella, V; Finnegan, L; Kaltenbach, K, 1998) |
| "in the treatment of opiate addiction." | ( Bearn, J; Gossop, M; Strang, J, 1999) |
| "To compare outcomes of patients with opioid dependence treated with MMT vs an alternative treatment, psychosocially enriched 180-day methadone-assisted detoxification." | ( Banys, P; Clark, HW; Delucchi, KL; Hall, SM; Masson, C; Robillard, H; Rosen, A; Sees, KL, 2000) |
| "Participants were opioid abusers entering methadone treatment." | ( Brooner, RK; Kidorf, MS; King, VL; Stoller, KB, 2000) |
| "Fifty-eight patients seeking treatment for opioid dependence were recruited in three outpatient facilities and randomly assigned to substitution with buprenorphine or methadone." | ( Déglon, JJ; Ladewig, D; Livoti, S; Petitjean, S; Stohler, R; Uehlinger, C; Waldvogel, D, 2001) |
| "The study was carried out on 44 opiate abusers (14 women aged from 21-33 years and 30 men aged from 21-46 years), who were classified to methadone maintenance treatment." | ( Janik, A; Kolarzyk, E; Kroch, S; Szpanowska-Wohn, A, 2000) |
| "Sufficient treatment facilities for opioid dependence should be provided when law enforcement activities against open drug scenes are planned." | ( Dürsteler-Mac Farland, KM; Eich, D; Eichenberger, A; Falcato, L; Rössler, W; Stohler, R, 2001) |
| "The treatment of opioid dependence during pregnancy is a major challenge for doctors, social workers and gynaecologists." | ( Eder, H; Fischer, G; Peternell, A; Rupp, I, 2001) |
| "Societal fears of opioid addiction and lack of advocacy are also causal factors in the under-treatment of pediatric pain." | ( Nichols, DG; Yaster, M, 2001) |
| "Methadone maintenance is an effective treatment for opioid dependence, yet its use is restricted to federally licensed narcotic treatment programs (NTPs)." | ( Chawarski, M; Fiellin, DA; O'Connor, PG; Pakes, JP; Pantalon, MV; Schottenfeld, RS, 2001) |
| "To review opioid dependence (OD) and its treatment." | ( Boardman, KD; Fye, CL; Raisch, DW; Sather, MR, 2002) |
| "The occurrence of an opioid addiction within an opioid treatment of pain or diarrhoea in inflammatory bowel disease is rarely reported." | ( Grandt, D; Häuser, W; Lachiheb, H, 2002) |
| "Methadone is widely used for the treatment of opioid dependence." | ( Baumann, P; Buclin, T; Eap, CB, 2002) |
| "Treatment of opiate dependence with naltrexone has been limited by poor compliance." | ( Church, SH; Collins, E; Kleber, HD; Nunes, EV; Rothenberg, JL; Seracini, A; Sullivan, MA, 2002) |
| "Prescription opioid abuse has harmful ramifications for the legitimate and appropriate use of opioids, including stigmatization, opiophobia, and undertreatment of pain." | ( Bigelow, G; Compton, P; Foley, K; Iguchi, M; Sannerud, C; Zacny, J, 2003) |
| "Pharmacological treatments for opiate dependence have had limited success; often the consequence of limited access to care." | ( Bridge, TP; Fudala, PJ; Herbert, S; Leiderman, DB, 2003) |
| "Men (N = 124) entering treatment for opioid dependence who were living with a family member were randomly assigned to one of two 24-week treatments: (a) behavioral family counseling (BFC) plus individual treatment (patients had both individual and family sessions and took naltrexone daily in presence of family member) or (b) individual-based treatment only (IBT; patients were given naltrexone and were asked in counseling sessions about their compliance, but there was no family involvement)." | ( Fals-Stewart, W; O'Farrell, TJ, 2003) |
| "Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone has been proposed, but its efficacy and safety have not been well studied." | ( Bridge, TP; Casadonte, P; Chiang, CN; Collins, J; Fudala, PJ; Goldsmith, RJ; Herbert, S; Jones, K; Ling, W; Malkerneker, U; McNicholas, L; Raisch, D; Renner, J; Stine, S; Tusel, D; Williford, WO, 2003) |
| "Mainstreaming opioid addiction treatment has many advantages; its success will depend on resolution of ethical and delivery system issues as well as improved and expanded training of physicians in addiction medicine." | ( Krantz, MJ; Mehler, PS, 2004) |
| "Improving office-based treatment of opioid dependence requires an evaluation of processes of care." | ( Chawarski, M; Fiellin, DA; O'Connor, PG; Schottenfeld, RS, 2004) |
| "In Australia, maintenance treatment for opioid dependence involves supervised daily administration of a dose of methadone or buprenorphine." | ( Bell, J; Byron, G; Gibson, A; Morris, A, 2004) |
| "Primary treatments for opiate dependence (e." | ( Levin, FR; Nunes, EV; Sullivan, MA, 2004) |
| "Data sources included opioid dependence treatment practice, review and outcome research literature (1965-2001) in the form of peer-reviewed articles, books, monographs and reports that are preeminently cited and reviewed international studies on MMT." | ( Fischer, B; Kim, G; Kirst, M; Rehm, J, 2005) |
| "Methadone is effective treatment for opioid addiction, but regulations restrict its use." | ( Awan, A; Brumback, LC; Carney, M; Donovan, D; Jackson, TR; Kapitan, S; Merrill, JO; Saxon, AJ; Schulman, BA, 2005) |
| "The results suggest that office-based treatment of opioid dependence is associated with new types of patients entering into treatment." | ( Chawarski, M; Fiellin, DA; O'Connor, PG; Schottenfeld, RS; Sullivan, LE, 2005) |
| "Methadone maintenance treatment of opiate addiction is highly effective at reducing drug use, drug-related criminal activity, and risk of HIV transmission." | ( Clarke, J; Key, RG; McKenzie, M; Poshkus, M; Rich, JD; Shield, DC; Wolf, FA, 2005) |
| "Treatment of maternal opioid dependence with methadone is associated with a delay in fetal heart rate (FHR) accelerations in nonstress tests." | ( Flores, S; McKay, J; Ramirez-Cacho, WA; Rayburn, WF; Schrader, RM, 2006) |
| "This formulation may offer effective treatment of opioid dependence and enhance treatment delivery while minimizing risks of patient non-adherence or illicit diversion of the medication." | ( Bigelow, GE; Moody, DE; Nuwayser, ES; Sigmon, SC, 2006) |
| "To describe the current situation of opiate addiction and treatments in China and make some suggestions." | ( Cubells, JF; Tang, YL; Zhao, C; Zhao, D, 2006) |
| "Currently, the main treatments for opiate dependence in China include short-term detoxification with opiate agonists or non-opiate agents, such as clonidine or lofexidine; Chinese herbal medicine and traditional non-medication treatments are also used." | ( Cubells, JF; Tang, YL; Zhao, C; Zhao, D, 2006) |
| "Treatment of opioid dependence often requires continued opioid administration in the form of substitution therapy, which means that opioid-using IDUs often continue receiving opioids even after cessation of illicit drug use." | ( Fairbairn, N; Kerr, T; Maas, B; Montaner, J; Wood, E, 2006) |
| "Buprenorphine (BUP) is effective in the treatment of opioid dependence when given on alternating days, probably as a result of long-lasting occupation of micro opioid receptors (microORs)." | ( Bueller, J; Chang, Y; Greenwald, M; Johanson, CE; Kilbourn, M; Koeppe, R; Moody, DE; Zubieta, JK, 2007) |
| "Many patients with chronic opioid dependence are referred to drug-free outpatient treatment following inpatient detoxification even though successful outpatient treatment engagement and abstinence from opioids occur only in a minority of cases." | ( Bush, KR; Calsyn, DA; Davis Correale, TM; Davison, JW; Kivlahan, DR; Reoux, JP; Sloan, KL; Sweeney, ML, 2006) |
| "Untreated opioid dependence is a major obstacle to the successful treatment and prevention of human immunodeficiency virus (HIV) infection." | ( Altice, FL; Basu, S; Eldred, L; Smith-Rohrberg, D; Stancliff, S; Sullivan, LE, 2006) |
| "Untreated opioid dependence adversely affects the care of human immunodeficiency virus (HIV)-positive patients." | ( Barry, D; Chawarski, MC; Fiellin, DA; Moore, BA; O'Connor, PG; Pantalon, MV; Schottenfeld, RS; Sullivan, LE; Tetrault, JM, 2006) |
| "Buprenorphine is used for the treatment of opioid dependence." | ( Bruce, RD; Kharasch, ED; McCance-Katz, E; Moody, DE; Morse, GD, 2006) |
| "Although treatment of opioid dependence is traditionally focused on heroin users, there is increasing recognition that a large number of people become dependent through the use of prescription opioids." | ( Lopatko, OV; White, JM, 2007) |
| "The most common treatment for opioid dependence is substitution therapy with another opioid such as methadone." | ( Barratt, DT; Coller, JK; Dahlen, K; Loennechen, MH; Somogyi, AA, 2006) |
| "Methadone maintenance therapy for the treatment of opioid dependence continues to carry a social stigma." | ( Bourgeois, JA; Craemer, E; Hancock, MM; Lester, L; Prosser, CC; Ransibrahmanakul, K; Rossaro, L, 2007) |
| "Patients suspected of opioid misuse can be treated with a time-limited trial of structured opioid therapy if they are not acquiring opioids from other sources." | ( Gourlay, D; Kahan, M; Midmer, D; Srivastava, A; Wilson, L, 2006) |
| "Another approach to treat opiate dependence could be to target the endogenous opioid system by enhancing the effects of enkephalins by protecting them from enzymic degradation by the dual peptidase inhibitor RB101." | ( Cordonnier, L; Noble, F; Roques, BP; Sanchez, M, 2007) |
| "Therefore, maintenance therapy for opioid dependence during pregnancy has been recommended to help withdrawal from street drugs, in order to improve maternal health and decrease risks to the fetus." | ( Halmesmäki, E; Haukkamaa, M; Kahila, H; Kivitie-Kallio, S; Saisto, T, 2007) |
| "Prescription opioid dependence is increasing, but treatment outcomes with office-based buprenorphine/naloxone among these patients have not been described." | ( Barry, DT; Chawarski, MC; Fiellin, DA; Moore, BA; O'Connor, PG; Schottenfeld, RS; Sullivan, LE, 2007) |
| "Among 212 patients who did not receive treatment for opioid dependence over the same period, the rates of treatment completion did not change significantly (89." | ( Rastegar, DA; Soeffing, JM, 2007) |
| "Naltrexone-treated opioid abusers demonstrate vulnerability to stress and drug-cue-induced craving and arousal responses that may contribute to the high rates of noncompliance and relapse among opioid-dependent individuals undergoing naltrexone treatment." | ( Doebrick, C; Fox, H; Hong, KI; Hyman, SM; Sinha, R, 2007) |
| "This study found that the frequency of opioid use disorders was 4 times higher in patients receiving opioid therapy compared with general population samples (3." | ( Balousek, SL; Brown, DD; Fleming, MF; Klessig, CL; Mundt, MP, 2007) |
| "Buprenorphine may be used to treat opioid dependence in office-based settings, but treatment models are needed to ensure access to psychosocial services needed by many patients." | ( Arnsten, JH; Gourevitch, MN; Kunins, HV; Whitley, SD, 2007) |
| "Buprenorphine is an efficacious treatment for opioid dependence recently approved for office-based medical practice." | ( Fong, C; Joseph, H; Kayman, DJ; Kolodny, A; Lee, SJ; Magura, S; Marsch, LA; Rosenblum, A; Salsitz, EA; Seewald, R; Taubes, T; Whitley, SD, 2007) |
| "The devastating costs of opioid abuse and dependence underscore the need for effective treatments for these disorders." | ( Comer, SD; Hulse, GK; Sullivan, MA, 2007) |
| "The problem of therapeutic opioid misuse largely affects patients who need opioids to treat chronic pain conditions." | ( Ballantyne, JC, 2007) |
| "We conclude that methadone maintenance treatment in opioid dependence shows positive effects on retention, opioid abuse and criminality compared with non-active controlled conditions." | ( Berglund, M; Johansson, BA; Lindgren, A, 2007) |
| "While opioid dependence has more treatment agents available than other abused drugs, none are curative." | ( Kleber, HD, 2007) |
| "To induce opiate dependence, mice were treated with intermittent escalating morphine doses (20-100 mg/kg, i." | ( Contarino, A; Ghozland, S; Ingallinesi, M; Koob, GF; Papaleo, F; Roberts, AJ, 2008) |
| "Prevalence of prescription opioid abuse has increased dramatically in recent years in the United States generally, and a similar pattern of increasing prescription opioid use has also been noted among patients seeking treatment for opioid dependence." | ( Dunn, KE; Heil, SH; Higgins, ST; McGee, MR; Sigmon, SC, 2008) |
| "Management of opioid dependence is associated with many challenges such as the misuse of prescribed treatment and lack of medication adherence that can affect the clinical outcome of the patient." | ( Jan, S; Kaur, AD; McQueen, A, 2008) |
| "All 47 pregnancies in 39 women with opiate dependence and buprenorphine maintenance treatment 2001-2006, and all 35 methadone-exposed pregnancies (26 women) 1982-2006 in Stockholm County." | ( Heilig, M; Kakko, J; Sarman, I, 2008) |
| "Since opioid dependence treatment with naltrexone tablets suffers from high dropout rates, several depot injections and implants are under investigation." | ( Bjørndal, A; Kornør, H; Kunøe, N; Lobmaier, P, 2008) |
| "Though useful in the treatment of opioid dependence and chronic pain, methadone possesses high abuse potential and documented mortality risks." | ( Gold, MS; Goldberger, BA; Graham, NA; Merlo, LJ, 2008) |
| "Providers of treatment for opioid addiction have entered a new era of accountability, as Federal and State regulators increasingly demand objective evidence of treatment effectiveness." | ( Jackson, TR, 2002) |
| "A new service delivery system for the treatment of opioid dependence, called motivational stepped care, matches the intensity of counseling services to each patient's clinical progress." | ( Brooner, RK; Kidorf, M, 2002) |
| "The success of maintenance treatment for opioid dependence in office-based settings is influenced by the extent of treatment coverage, the availability of effective medications and the capacity of general practitioners to prescribe opioids in adequate doses with a minimum of concomitant benzodiazepine prescriptions." | ( Aeschbach Jachmann, C; Fischer, G; Jagsch, R; Matzenauer, C; Winklbaur, B, 2008) |
| "The Prescription Opioid Misuse Index (POMI) was developed and used in a larger study designed to assess correlates of OxyContin abuse in pain patients prescribed OxyContin, patients treated for OxyContin addiction, and individuals incarcerated for OxyContin-related charges." | ( Campbell, ED; Cropsey, KL; Knisely, JS; Wunsch, MJ, 2008) |
| "Buprenorphine should be used for opiate dependence and chronic pain in patients with methadone-induced QT prolongation and as first line therapy in patients with risk factors for torsades de pointes." | ( Do, LT; Esses, JL; Hanon, S; Rosman, J; Schweitzer, P, 2008) |
| "As the only pharmacological treatment for opioid dependence readily available in office-based settings, buprenorphine may facilitate a historic shift in addiction treatment from treatment facilities to general medical practices." | ( Botsko, M; Cunningham, CO; Egan, JE; Fiellin, DA; Finkelstein, R; Gourevitch, MN; Netherland, J; Renner, JA; Saxon, AJ; Sohler, N; Sullivan, LE; Weiss, L, 2009) |
| "To determine whether prescription opioid dependence, assessed at the beginning of rehabilitation treatment, is associated with poorer treatment outcomes in patients with CDOSDs attending an interdisciplinary rehabilitation program." | ( Dersh, J; Gatchel, RJ; Mayer, EA; Mayer, TG; Polatin, PB; Theodore, BR, 2008) |
| "The cost of providing and receiving treatment for opioid dependence can determine its adoption." | ( Fiellin, DA; Jones, ES; Moore, BA; O'Connor, PG; Schottenfeld, RS; Sindelar, JL, 2009) |
| "Controls had not developed prescription opioid addiction as measured in part by close monitoring on long-term opioid therapy at a pain management center." | ( Bieber, CM; Borsook, D; Brennan, MJ; Butler, SF; Fernandez, K; Jamison, RN; Katz, NP; Osgood, E; Sharpe-Potter, J; Thomson, HN; Weiss, RD, 2008) |
| "Women using methadone for treatment of opioid dependence should not be discouraged from breastfeeding." | ( Finkelstein, Y; Garcia-Bournissen, F; Glatstein, MM; Koren, G, 2008) |
| "Buprenorphine can be used for the treatment of opioid dependence in primary care settings." | ( DiRocco, D; Gourevitch, MN; Grossman, E; Lee, JD, 2009) |
| "Opioid-substitution treatment (OST) for opioid dependence (OD) has proven effective in retaining patients in treatment and reducing illegal opiate abuse and crime." | ( Alho, H; Fabritius, C; Kalska, H; Rapeli, P, 2009) |
| "As a treatment agent for opioid dependence, buprenorphine is a nearly ideal medication at our current stage of medication development." | ( Ling, W, 2009) |
| "The development of effective treatments for opioid dependence is of great importance given the devastating consequences of the disease." | ( Dodrill, CL; Kosten, TR; Stotts, AL, 2009) |
| "The prescription of buprenorphine for opioid dependence treatment can be incorporated into primary care practice, and many patients, including polysubstance users, benefit from this treatment." | ( Fingerhood, MI; Jasinski, DR; Martin, LD; Rastegar, DA; Soeffing, JM, 2009) |
| "Methadone is a proven first-line treatment in opioid dependence but few studies have addressed the efficacy of different isoforms of methadone or the transfer from one form to the other." | ( Soyka, M; Zingg, C, 2009) |
| "HIV-infected patients with opioid dependence often require opioid replacement therapy." | ( Altice, FL; Andrews, L; Bruce, RD; Conner, C; Fang, WB; Friedland, GH; Lin, SN; Moody, DE; Piliero, PJ; Sabo, JP; Wruck, JM, 2009) |
| "Methadone is highly effective in treating opioid dependence, and it is also used as an analgesic for second-line management of chronic pain." | ( Brooks, D; Modesto-Lowe, V; Petry, N, 2010) |
| "Physician adoption of buprenorphine treatment of opioid dependence may be limited in part by concerns regarding the induction process." | ( Bryan, B; Fiellin, DA; Gunderson, EW; Levin, FR; Wang, XQ, 2010) |
| "It is imperative that opioid dependence is addressed and treated properly, in order to return patients to being productive participants in the workplace and society." | ( Jan, SA, 2010) |
| "In response to the growing incidence of opioid dependence, guidelines have been created, and new treatments are being developed to assist physicians in treating dependence and withdrawal of opioids." | ( Bragaw, L; Nicholls, L; Ruetsch, C, 2010) |
| "Guidelines for the treatment of opioid dependence have been developed by organizations such as the American Society of Interventional Pain Physicians (ASIPP) and the American Psychiatric Association (APA)." | ( Bragaw, L; Nicholls, L; Ruetsch, C, 2010) |
| "In order to be successful in managing opioid dependence, physicians, employers, and managed care organizations must work together to provide an integrated approach to treatment." | ( Jan, SA, 2010) |
| "Failure in treating opioid dependence is costly to the patient, the employer, managed care organizations, and the overall health care system." | ( Ruetsch, C, 2010) |
| "Pharmacotherapy of opioid addiction alone is usually insufficient, and a complete treatment should also include effective psychosocial support or other interventions." | ( Bramness, J; Gossop, M; Lobmaier, P; Waal, H, 2010) |
| "Undertreated pain and prescription opioid abuse remain important public health problems." | ( Fine, PG; Webster, LR, 2010) |
| "In 4 studies with comparison groups, opioid misuse was modestly reduced (7% to 23%) after treatment agreements with or without urine drug testing." | ( Alford, DP; Becker, WC; Kapoor, A; Starrels, JL; Turner, BJ; Williams, AR, 2010) |
| "Naltrexone's usefulness in the treatment of opioid dependence stems from its ability to block the action of heroin and other opioids." | ( Gossop, M; Hegstad, S; Hjerkinn, B; Kristensen, O; Kunøe, N; Lobmaier, P; Vederhus, JK; Waal, H, 2010) |
| "Office-based treatment of opioid dependence with buprenorphine has the potential to expand treatment capacity in the United States." | ( Arfken, CL; di Menza, S; Johanson, CE; Schuster, CR, 2010) |
| "To outline the management of opioid dependence using opioid pharmacotherapy as part of a comprehensive chronic illness management strategy." | ( Frei, M, 2010) |
| "Limitations of existing pharmacological treatments for opioid dependence include low adherence, medication diversion, and emergence of withdrawal symptoms." | ( Bailey, GL; Beebe, KL; Bigelow, G; Casadonte, P; Kampman, KM; Ling, W; Patkar, A; Rosenthal, RN, 2010) |
| "In addition to treatment for opioid dependence, addressing other substance use, social issues, particularly housing, and mental health may have important implications for reducing HIV transmission in HIV-infected opioid-dependent patients." | ( Botsko, M; Chaudhry, AA; Egan, JE; Estrada, B; Fiellin, DA; Flanigan, TP; Lucas, GM; Mitty, J; Weiss, L; Woodson, T, 2011) |
| "Having opioid dependence and HIV infection are associated with poor HIV-related treatment outcomes." | ( Altice, FL; Botsko, M; Bruce, RD; Cajina, A; Cunningham, CO; Fiellin, DA; Finkelstein, R; Flanigan, TP; Gourevitch, MN; Korthuis, PT; Lucas, GM; Lum, PJ; Nandi, V; Sullivan, LE; Vergara-Rodriguez, P, 2011) |
| "Naltrexone can be used to treat opioid dependence, but patients refuse to take it." | ( Aklin, WM; Bigelow, GE; DeFulio, A; Donlin, WD; Everly, JJ; Fingerhood, M; Koffarnus, MN; Leoutsakos, JM; Silverman, K; Umbricht, A, 2011) |
| "Chronic medical conditions such as opioid dependence require evidence-based treatment recommendations." | ( Arria, A; Aschauer, C; Bäwert, A; Fischer, G; Jagsch, R; Jones, H; Leitich, H; Rohrmeister, K; Unger, A; Winklbaur, B, 2011) |
| "The influence of alcohol use on opioid dependence is a major problem that warrants a search for more effective treatment strategies." | ( Gorelick, DA; Mannelli, P; Patkar, AA; Peindl, K; Tharwani, HM; Wu, LT, 2011) |
| "Individuals with problem drinking and opioid dependence who were treated with VLNTX (n = 55) showed reduced withdrawal (p = ." | ( Gorelick, DA; Mannelli, P; Patkar, AA; Peindl, K; Tharwani, HM; Wu, LT, 2011) |
| "Treatment options for opioid dependence and pain are reviewed, including the use of the partial µ agonist buprenorphine in the management of concurrent pain and opioid addiction." | ( Hillhouse, M; Ling, W; Mooney, L, 2011) |
| "As office-based opioid dependence treatment (OBOT) has grown in the United States, postmarketing surveillance data reveal increased reports of buprenorphine misuse and diversion." | ( Lofwall, MR; Nuzzo, PA; Walsh, SL; Wunsch, MJ, 2011) |
| "There are three approaches to treating opioid dependence." | ( Law, F; Melichar, J; O'Shea, J, 2009) |
| "An accurate prevalence estimate for opioid dependence in New Zealand, and hence the extent of unmet treatment need, is lacking." | ( Adamson, SJ; Campbell, SD; Deering, DE; Frampton, CM; Henderson, C; Pooley, S; Robertson, R; Sellman, JD; Sheridan, J, 2012) |
| "Dentists can play a role in minimizing opioid abuse through patient education, careful patient assessment and referral for substance abuse treatment when indicated, and using tools such as prescription monitoring programs." | ( Denisco, RC; Hersh, EV; Kane, WT; Katz, NP; Kenna, GA; Kulich, RJ; Mehta, NR; Moore, PA; O'Neil, MG, 2011) |
| "Patients with opioid dependence who received medication for this disorder had lower hospital utilization and total costs than patients who did not receive pharmacologic therapy." | ( Baser, O; Chalk, M; Fiellin, DA; Gastfriend, DR, 2011) |
| "Treated patients with opiate dependence showed improvement in Stroop test performance under painful conditions, and this improvement was greater in males than females." | ( Aniskin, DB; Boda, N; Cohen, LJ; Fink, E; Galynker, II; Prosser, J; Steinfeld, M, 2011) |
| "The rate of opioid addiction among patients receiving long-term opioid therapy remains unclear, but research suggests that opioid misuse is not rare." | ( Chou, R; Deyo, RA; Kolodny, A; Von Korff, M, 2011) |
| "There are three stages to treating opioid dependence." | ( Law, F; Melichar, J; O'Shea, J; Praveen, KT, 2011) |
| "Here, we argue that opiate addiction and psychostimulant addiction are behaviourally and neurobiologically distinct and that the differences have important implications for addiction treatment, addiction theories and future research." | ( Badiani, A; Belin, D; Calu, D; Epstein, D; Shaham, Y, 2011) |
| "From 2006-2010, 228 patients with opiate abuse/dependence were treated with buprenorphine/naloxone using a home-induction protocol." | ( Becker, W; Doolittle, B, 2011) |
| "In the study, 791 opioid abusers completed a one-time structured interview, including complete histories of illicit and prescription drug abuse and route of drug administration." | ( Cicero, TJ; Kurtz, SP; Surratt, H, 2011) |
| "Outpatient non-dependent opioid abusers (N=27) were randomly assigned to a single double-blind IM administration of 75, 150, or 300 mg XR-NTX." | ( Bigelow, GE; Dong, Q; Gastfriend, DR; Preston, KL; Schmittner, J, 2012) |
| "Suspected opioid addiction is managed with structured opioid therapy, methadone or buprenorphine treatment, or abstinence-based treatment." | ( Kahan, M; Mailis-Gagnon, A; Srivastava, A; Wilson, L, 2011) |
| "However, the percentage of new opioid dependence treatment episodes involving an opioid agonist is unchanged, suggesting the need for further efforts to increase buprenorphine use among urban populations." | ( Dick, AW; Farmer, C; Gordon, AJ; Schuster, J; Sorbero, M; Stein, BD, 2012) |
| "Although use of buprenorphine in the treatment of opioid dependence is expected to continue to increase, little is known about the optimal setting for providing the medical and psychosocial care required with buprenorphine pharmacotherapy." | ( Charuvastra, C; Cunningham-Rathner, J; Donovick, R; Esagoff, AE; Hillhouse, M; Ling, W; Miotto, K; Torrington, M, 2012) |
| "Constant refinement of opioid dependence (OD) therapies is a condition to promote treatment access and delivery." | ( Bhatia, KS; Lee, T; Mannelli, P; Peindl, KS; Wu, LT, 2012) |
| "Buprenorphine/naloxone is used for the treatment of opioid dependence." | ( Pletsch, G; Rodgman, C, 2012) |
| "The public health problem of opioid dependence and its treatment during pregnancy is reviewed first." | ( Chisolm, MS; Jansson, LM; Jones, HE; Terplan, M, 2013) |
| "Moreover, for a full remission of opioid addiction to be sustainable, both post-partum and across the lifespan, treatment providers must not rely solely on medication to treat their patients but should also utilize women-specific comprehensive treatment models that address the underlying multifaceted complexities of their patient's lives." | ( Finnegan, LP; Jones, HE; Kaltenbach, K, 2012) |
| "The cohort of women treated for opioid dependence during pregnancy with medication-assisted therapy and delivered at a single institution between 2000 and 2006 were retrospectively identified (n = 149 women; n = 151 neonates)." | ( Benvenuto, A; Howard, D; Johnston, A; Mandell, T; Metayer, J; Meyer, M; Plante, D, 2012) |
| "Buprenorphine's stabilization of opioid dependence and HIV disease may permit the use of HCV therapy over time." | ( Flanigan, TP; Friedmann, PD; Macleod, CJ; Maynard, MA; Rich, JD; Sylvestre, DL; Taylor, LE, 2012) |
| "Buprenorphine as maintenance treatment of opioid dependence during pregnancy has promise and may offer some benefits, but more research is needed, especially regarding induction of actively addicted women during pregnancy." | ( Martin, PR; Young, JL, 2012) |
| "Most opioid abusers tamper with tablets to facilitate oral, intranasal, or intravenous administration, whereas compliant patients usually take intact tablets." | ( Barkin, RL; Bruckenthal, P; Stanos, SP, 2012) |
| "To assess the incidence or prevalence of opioid dependence syndrome in adults (with and without previous history of substance abuse) following treatment with opioid analgesics for pain relief." | ( Amato, L; Davoli, M; Minozzi, S, 2013) |
| "The implementation of MAT for opioid use disorders by specialty addiction treatment programs may be facilitated by Medicaid but may be impeded by reliance on funding from the criminal justice system." | ( Knudsen, HK; Roman, PM, 2012) |
| "Treatment for opiate addiction requires long-term management." | ( Bart, G, 2012) |
| "In this review we discuss opioid abuse and misuse issues that often arise in the treatment of patients with chronic pain, and present an overview of assessment and treatment strategies that can be effective in improving outcomes associated with the use of prescription opioids for pain." | ( Edwards, RR; Jamison, RN, 2013) |
| "Untreated opioid dependence adversely affects HIV outcomes." | ( Barry, DT; Fiellin, DA; Fiellin, LE; Moore, BA; O'Connor, PG; Schottenfeld, R; Tetrault, JM, 2012) |
| "Using buprenorphine as a medication to treat opioid dependence is becoming more prevalent as illicit opiate use increases." | ( Canamar, CP; Hillhouse, M; Ling, W, 2013) |
| "Individuals with pain seeking BNT for opioid dependence report a wide range of conventional, complementary, and alternative pain-related treatments and are interested (especially those with CP) in receiving pain management services along with BNT." | ( Barry, DT; Beitel, M; Cutter, CJ; Fiellin, DA; Moore, BA; Savant, JD; Schottenfeld, RS, 2012) |
| "Medically assisted treatment for opiate addiction with Suboxone is conducted in outpatient setting with the involvement of close relatives who are not addicted." | ( Delić, A; Hasanović, M; Kuldija, A; Pajević, I, 2012) |
| "In response to disturbing rises in prescription opioid abuse, the US Food and Drug Administration (FDA) has proposed the implementation of aggressive Risk Evaluation and Mitigation Strategies (REMS)." | ( Craig, D; Giarratano, A; Mercadante, S, 2012) |
| "The field of opioid dependence treatment is poised to undergo a process of reinforcement and transformation." | ( Bascaran, MT; Bobes, J; Bobes-Bascaran, MT; Garcia-Portilla, MP; Saiz, PA, 2014) |
| "Lessons learned in research and treatment of opioid dependence demonstrate the need to include pregnant women in clinical trials." | ( Baewert, A; Fischer, G; Graf-Rohrmeister, K; Jagsch, R; Langer, M; Thau, K; Unger, A; Winklbaur-Hausknost, B, 2013) |
| "Buprenorphine is an effective treatment for opioid dependence that can be provided in a primary care setting." | ( Jacapraro, JS; Rastegar, DA; Rowe, TA, 2012) |
| "Offering treatment for opioid dependence with buprenorphine in a primary care practice is associated with the identification and treatment of other chronic medical conditions." | ( Jacapraro, JS; Rastegar, DA; Rowe, TA, 2012) |
| "Methadone, used both to treat opioid addiction and to manage chronic pain, is commonly prescribed as an opioid of choice for patients with chronic pain and comorbid substance use disorders." | ( Friedman, CK; Reisfield, GM, 2012) |
| "Buprenorphine is well known in the treatment of opioid dependence." | ( Apelt, SM; Backmund, M; Gölz, J; Scherbaum, N; Soyka, M, 2013) |
| "Having an earlier onset of prescription opioid use disorder and a history of bipolar disorder, major depression disorder, specific phobia and cluster B personality disorders predicted shorter delays to treatment." | ( Blanco, C; Iza, M; Olfson, M; Rafful, C; Schwartz, RP; Wang, S, 2013) |
| "Despite no pre-treatment differences in opioid dependence severity, women reported significantly greater functional impairment, greater psychiatric severity, and higher likelihood of using opioids to cope with negative affect and pain than men." | ( Carroll, KM; Connery, HS; Devito, EE; Dodd, D; Greenfield, SF; McHugh, RK; Potter, JS; Weiss, RD, 2013) |
| "Prescription opioid dependence is a growing problem, but little research exists on its treatment, including patient characteristics that predict treatment outcome." | ( Dreifuss, JA; Fiellin, DA; Fitzmaurice, GM; Frost, K; Griffin, ML; Hatch-Maillette, M; Potter, JS; Selzer, J; Sonne, SC; Weiss, RD, 2013) |
| "While methadone effectively treats opiate dependence, the side effect of erectile dysfunction (ED) may interfere with treatment adherence and benefits." | ( Abdul Aziz, S; Baharudin, A; Das, S; Ibrahim, N; Midin, M; Mislan, N; Nik Jaafar, NR; Sidi, H, 2013) |
| "Patients with opioid addiction who receive prescription opioids for treatment of nonmalignant chronic pain present a therapeutic challenge." | ( Azadfard, M; Blondell, RD; Giambrone, AK; Homish, GG; Jaanimägi, U; Kowalik, U; Lozano, JR; Neumann, AM, 2013) |
| "In this study, 152 individuals seeking treatment for opioid dependence were randomized to a 2-week detoxification with buprenorphine-naloxone (DETOX) or 12weeks of buprenorphine-naloxone (BUP), each with weekly individual and group drug counseling." | ( Bogenschutz, MP; Nakazawa, M; Wilcox, CE; Woody, G, 2013) |
| "With increasing rates of opioid abuse and dependence, and the availability of medication-assisted treatment, one strategy to improve resident skills is to incorporate buprenorphine treatment into training settings." | ( Cunningham, CO; Giovanniello, A; Kunins, HV; Sohler, NL; Thompson, D, 2013) |
| "Younger age, longer duration of the opioid abuse, and higher subjective opiate intoxication severity before treatment entry were all significantly associated with negative treatment outcome." | ( Dezfouli, A; Ekhtiari, H; Ghodousi, A; Mokri, A; Zamanian, B, 2013) |
| "Two commonly prescribed treatments for opioid addiction are methadone and buprenorphine." | ( Ambrose-Lanci, LM; Ang, A; Berrettini, WH; Bruce, RD; Clarke, TK; Crist, RC; Hillhouse, MP; Ling, W; Lohoff, FW; Saxon, AJ; Woody, G, 2014) |
| "Naltrexone implants are used to treat opioid dependence, but their safety and efficacy remain poorly understood." | ( Degenhardt, L; Farrell, M; Gowing, L; Hall, W; Larney, S; Mattick, RP, 2014) |
| "This review discusses the problem of prescription opioid abuse and strategies to minimize risk within the context of acute pain treatment, and explores the potential role of tamper-resistant opioid formulations and other abuse deterrence strategies in the area of acute or persistent acute pain management." | ( Passik, SD, 2014) |
| "In order to stem the tide of prescription opioid abuse and preserve the availability of opioids as a much needed analgesic option, a multifaceted approach that includes tamper-resistant opioid formulations-for chronic or acute pain-along with strategies such as improved patient risk assessment, funding for and referral to addiction treatment programs, greater use of PMPs, and raised awareness of prescription opioid abuse is needed." | ( Passik, SD, 2014) |
| "In the United States, opioid abuse and dependence continue to be a growing problem, whereas treatment for opioid abuse and dependence remains fairly static." | ( Cunningham, CO; Fox, AD; Lopez, CM; Shah, PA; Sohler, NL; Starrels, JL, 2014) |
| "The MORE group, who reported decreased opioid misuse and opioid craving during treatment, evidenced less subjective opioid cue-reactivity, greater HR decelerations, and greater increases in HRV to all cues after treatment compared to the SG; HR and HRV effects were most pronounced for natural reward cues." | ( Froeliger, B; Garland, EL; Howard, MO, 2014) |
| "CRAFT-T is a promising treatment for opioid use disorder but replication is needed to confirm these results." | ( Brigham, GS; Guo, X; Lewis, DF; Slesnick, N; Somoza, E; Winhusen, TM, 2014) |
| "Naltrexone is effective in treating opioid dependence by blocking µ, κ and δ opiate receptors." | ( Atayee, RS; Best, BM; Liu, JC; Ma, JD; Morello, CM, 2014) |
| "Methadone is used for the treatment of opioid addiction and for treatment of chronic pain." | ( Chou, R; Compton, P; Cruciani, RA; Farrar, JT; Fiellin, DA; Haigney, MC; Inturrisi, C; Knight, JR; Marcus, SM; Mehta, D; Meyer, MC; Otis-Green, S; Portenoy, R; Savage, S; Strain, E; Walsh, S; Zeltzer, L, 2014) |
| "In patients prescribed methadone for treatment of opioid dependence, data suggest that mortality benefits related to reduction in illicit drug use outweigh harms." | ( Chou, R; Dana, T; Weimer, MB, 2014) |
| "Rates of opioid abuse were higher among patients who switched to other ER/LA opioids or discontinued ER/LA opioid treatment, suggesting that abusers may seek more easily abuseable alternatives such as prescription opioids without abuse-deterrent technology." | ( Ben-Joseph, R; Birnbaum, HG; Kirson, NY; Michna, E; Shei, A, 2014) |
| "Some opioid abusers use intravenous administration to increase the magnitude of positive reinforcing effects." | ( Bartlett, C; Colucci, SV; Harris, SC; Perrino, PJ; Shram, M; Wang, Y, 2014) |
| "Relevant search terms included opioid, opioid abuse, chronic pain management, written care agreements, urine drug testing, and multimodal therapy." | ( Provenzano, DA; Viscusi, ER, 2014) |
| "Treatment of opioid dependence by office-based buprenorphine and methadone maintenance programs has expanded opportunities for therapy." | ( Kaye, AD; Mitra, S; Urman, RD; Vadivelu, N, 2014) |
| "In the multi-site Prescription Opioid Addiction Treatment Study (POATS), conducted within the National Drug Abuse Clinical Trials Network, participants randomly assigned to receive individual drug counseling in addition to buprenorphine-naloxone and medical management did not have superior opioid use outcomes." | ( Carroll, KM; Connery, HS; Dodd, DR; Dreifuss, JA; Griffin, ML; Potter, JS; Weiss, RD, 2014) |
| "Amid the global transition to treat opioid addiction as an illness, many people who inject drugs (PWID) face heterogeneous legal environments that include both punitive and harm reduction measures." | ( Binh, NT; Celentano, DD; Dat, do T; Go, VF; Huong, NM; Quan, VM; Tomori, C; Tuan, le N; Zelaya, CE, 2014) |
| "Use of methadone for the treatment of opioid addiction is an effective harm-reduction approach, although variability in treatment outcomes among individuals has been reported." | ( Anglin, R; Bawor, M; Dennis, BB; Samaan, Z; Steiner, M; Thabane, L, 2014) |
| "In men seeking treatment for opioid dependence sexual dysfunction was recorded in 48% by ASEX, and in at least one of the domains in 92% by IIEF and in 90% by CSFQ; in comparison with the healthy controls, the prevalence of sexual dysfunction in patients with opioid dependence was significantly higher by each measure." | ( Grover, S; Mattoo, SK; Venkatesh, K, 2014) |
| "Opioid substitution treatment (OST) for opioid dependence may be limited by adverse events (AEs)." | ( Babic-Hohnjec, L; Berthel, T; Bonorden-Kleij, K; Gholami, N; Haasen, C; Hämmig, R; Höpner, D; Köhler, W; Lebentrau, K; Reimer, J; Ruckes, C; Verthein, U; Vollmert, C; Weber, B, 2014) |
| "Prior treatment for opioid dependence significantly moderated the additional improvement of CRA+ for longest continuous days of abstinence." | ( Bickel, WK; Chopra, MP; Christensen, DR; Jackson, L; Landes, RD; Mancino, MJ; Marsch, LA, 2014) |
| "The major problem in the treatment of opioid dependence still remains the occurrence of relapse, to which stressful life events, renewed use of heroin, and exposure to drug-associated environmental cues are all positively correlated." | ( Antinori, S; Fadda, P; Fattore, L; Fratta, W, 2015) |
| "Prescription opioid dependence is increasing and creates a significant public health burden, but primary care physicians lack evidence-based guidelines to decide between tapering doses followed by discontinuation of buprenorphine hydrochloride and naloxone hydrochloride therapy (hereinafter referred to as buprenorphine therapy) or ongoing maintenance therapy." | ( Barry, DT; Cutter, CJ; Fiellin, DA; Moore, BA; O'Connor, PG; Schottenfeld, RS, 2014) |
| "Medication assisted treatment for opioid dependence alters the pain experience." | ( Gonzalez, G; Wachholtz, A, 2014) |
| "Implications for treating co-morbid opioid addiction and pain (acute and chronic) are discussed." | ( Gonzalez, G; Wachholtz, A, 2014) |
| "Treating opioid dependence, however, should ideally improve other aspects of overall health, including preventive services." | ( Altice, FL; Haddad, MS; Zelenev, A, 2015) |
| "Individuals being treated for opioid dependence had a more than fourfold increase of mortality risk compared with the general population [SMR = 4." | ( Evans, E; Hser, YI; Huang, D; Li, L; Liu, L; Min, J; Nosyk, B; Urada, D, 2015) |
| "In people with opiate dependence, detoxification and methadone maintenance treatment both independently reduce the instantaneous hazard of all-cause and drug-related mortality." | ( Evans, E; Hser, YI; Huang, D; Li, L; Liu, L; Min, J; Nosyk, B; Urada, D, 2015) |
| "While opioid dependence is a complex health condition, the treatment of HIV-infected individuals with opioid dependence presents additional challenges." | ( Abood, ME; Benamar, K; Palma, J, 2015) |
| "The use of buprenorphine products to treat opioid dependence has increased significantly in the past 10 years and has shifted to greater use by primary care physicians, indicating a rapidly changing face of opioid maintenance therapy in the United States." | ( Alexander, GC; Kruszewski, SP; Turner, L, 2015) |
| "Therapeutic approaches for the treatment of opioid dependence are total abstinence and opioid agonist maintenance treatment (OAMT)." | ( Carmel, Z; Goren, L; Marchevsky, S, 2014) |
| "In the treatment of opioid dependence, total direct medical costs for Medicaid would be lower for sublingual film treated patients, at current drug prices." | ( Aballéa, S; Asche, CV; Clay, E; Kharitonova, E; Ruby, J; Zah, V, 2015) |
| "Ninety-four patients with opioid dependence under maintenance methadone treatment were consecutively recruited." | ( Chericoni, S; Daini, L; Giarratana, T; Meini, M; Moncini, M; Rucci, P; Scaramelli, D; Stefanelli, F, 2015) |
| "Methadone has been used to treat opiate dependence since the mid-1960s." | ( Kydd, R; Russell, BR; Wang, GY, 2015) |
| "Patients with opioid use disorders frequently discontinue opioid maintenance therapy (OMT) prematurely, reducing retention and possibly limiting the efficacy of OMT." | ( Aronson, G; Back, SE; Barth, KS; Bentzley, BS; Book, SW, 2015) |
| "Methadone is an effective treatment for opioid dependence." | ( Clarke, J; Larney, S; McKenzie, M; Noska, A; Reddy, M; Rich, JD; Tran, L; Wong, JB; Zaller, N, 2015) |
| "Patients with opioid use disorders on opioid agonist therapy (OAT) have lower pain tolerance compared to controls." | ( Alford, DP; Cheng, DM; Edwards, RR; Liebschutz, JM; Lira, MC; Mao, J; Samet, JH; Tsui, JI; Winter, MR, 2015) |
| "Methadone maintenance has dominated opiate addiction treatment in the United States for decades." | ( Harris, S, 2015) |
| "Since opioid misuse continues to be prevalent despite attempts at reformulations to make the drugs crush resistant, a high degree of clinical suspicion is needed to evaluate and treat patients who present with unique findings after episodes of substance abuse, especially those related to tamper-resistant formulations." | ( MacDonald, LE; Mullins-Hodgin, R; Onsrud, JE, 2015) |
| "Due to the high prevalence of prescription opioid misuse, the US Food and Drug Administration (FDA) mandated a Risk Evaluation and Mitigation Strategy (REMS) requiring manufacturers of extended-release/long-acting (ER/LA) opioid analgesics to fund continuing education based on a FDA Blueprint." | ( Alford, DP; Hardesty, I; Hayes, SM; Ng, P; Peloquin, S; White, JL; Zisblatt, L, 2016) |
| "Induction is a crucial period of opioid addiction treatment." | ( Ang, A; Blaine, JD; Hillhouse, MP; Jacobs, P; Mai, BE; Mooney, LJ; Nielsen, S; S Potter, J; Saxon, AJ; Wakim, PG, 2015) |
| "The heritability of opioid use disorder has been widely investigated; however, the influence of specific genes on methadone treatment outcomes is not well understood." | ( Anglin, R; Bawor, M; Daiter, J; Dennis, BB; Desai, D; Marsh, DC; Pare, G; Plater, C; Samaan, Z; Steiner, M; Tan, C; Thabane, L; Varenbut, M; Worster, A, 2015) |
| "Adults treated for opioid dependence during April 2005 to March 2009: 151,983 individuals; 69% male; median age 32." | ( Bird, SM; Dunn, G; Hickman, M; Jones, A; Marsden, J; Millar, T; Pierce, M, 2016) |
| "The syndemic of opioid addiction, HIV, hepatitis, tuberculosis, imprisonment, and overdose in Russia has been worsened by the illegality of opioid substitution therapy." | ( Barbour, R; Heimer, R; Levina, OS; Lyubimova, A, 2016) |
| "Buprenorphine was approved for the treatment of opioid dependence in 2002 after the passage of Drug Abuse Treatment Act 2000 (DATA 2000) which allowed clinicians to treat opioid-dependent patients with specifically named opioid agonist therapies in an office setting." | ( Wiegand, TJ, 2016) |
| "Among patients with opioid use disorder in Iran, sublingual buprenorphine/naloxone was associated with a greater number of opioid-negative urine tests and treatment retention than oral naltrexone, but not significantly greater initial abstinence duration or proportions with sustained abstinence." | ( Chawarski, MC; Mokri, A; Schottenfeld, RS; Taherinakhost, H, 2016) |
| "A major goal for the treatment of opioid use disorder is to reduce or eliminate the use of illicit opioids." | ( Fudala, PJ; Greenwald, MK; Heidbreder, C; Jones, JP; Liu, Y; Nasser, AF; Twumasi-Ankrah, P; Vince, B, 2016) |
| "Adults with opioid dependence (n=283) were recruited from two integrated health systems to participate in interviews focused on prior experiences with treatment for opioid dependence, knowledge of medication options, preferences for treatment, and experiences with treatment for chronic pain in the context of problems with opioids." | ( Green, CA; McCarty, D; Mertens, J; Stumbo, SP; Weisner, C; Yarborough, BJ, 2016) |
| "Growing rates of opioid abuse and overdose throughout the nation have lead some community organizations to develop naloxone administration programs." | ( Kitch, BB; Portela, RC, 2016) |
| "Buprenorphine, used to treat opioid use disorder and chronic pain, is a partial nociceptin opioid receptor agonist." | ( Batki, SL; Bertenthal, D; Madden, E; Maguen, S; Neylan, TC; Seal, KH; Stein, MB; Striebel, J, 2016) |
| "The strategies to prevent opioid abuse and to maintain opioid therapy when medically necessary fall into primary and secondary prevention categories." | ( Kaye, AD; Kaye, AM; Manchikanti, L, 2016) |
| "Individuals with opioid use disorders, including those on medication-assisted therapy such as methadone or buprenorphine, are a key demographic group that can benefit from HCV treatment given their high HCV prevalence; however, pharmacokinetic and pharmacodynamic drug interactions could blunt their utility." | ( Bruce, RD; Friedland, G; Ogbuagu, O, 2016) |
| "Opioid agonist therapies (OAT) to treat opioid addiction in people who inject drugs (PWID) began in Ukraine in 2004." | ( Altice, FL; Bojko, MJ; Dvoriak, S; Filippovych, S; Islam, Z; Makarenko, I; Marcus, R; Mazhnaya, A, 2016) |
| "Methadone maintenance is an effective treatment for opioid dependence but is rarely initiated in US jails." | ( Dunlap, L; Jaffe, JH; Kelly, SM; Mitchell, SG; O'Grady, KE; Schwartz, RP; Sharma, A; Zarkin, GA, 2016) |
| "Treatment of opioid dependence with buprenorphine improves outcomes." | ( Alho, H; D'Agnone, O; Krajci, P; Littlewood, R; Maremmani, I; Reimer, J; Rolland, B; Roncero, C; Simon, N; Somaini, L; Wright, N, 2016) |
| "The effectiveness of buprenorphine treatment of opioid dependence is limited by suboptimal medication adherence, abuse, and diversion." | ( Beebe, KL; Chen, M; Kim, S; Lofwall, MR; Rosenthal, RN; Vocci, FJ, 2016) |
| "Legally prescribed opioid dependence was belatedly diagnosed in 60 patients in a University hospital, after prolonged use of drugs to treat chronic pain and with low adherence to pain scale or guidelines." | ( Agudelo, Y; Alarcon-Franco, L; Garcia-Orjuela, MG; Sanchez-Fernandez, JC; Zuluaga, AF, 2016) |
| "has paralleled increases in opioid addictions and overdoses, requiring new preventative, diagnostic, and treatment strategies." | ( Bell, RL; Chambers, RA; Engleman, EA; Greene, MS; Sajid, A; Whiteman, A, 2016) |
| "These findings demonstrate that opioid addiction in patients with complex addictions and mental illnesses comorbidities can show effective treatment responses as measured by PDMP tracking of decreases in opioid prescriptions to those patients." | ( Bell, RL; Chambers, RA; Engleman, EA; Greene, MS; Sajid, A; Whiteman, A, 2016) |
| "Treatment-seeking adults with opioid dependence completed self-report measures including past-month opioid use and the Monetary Choice Questionnaire (Kirby and Marakovic, 1996; Kirby et al." | ( Bailey, AJ; Borges, AM; Griffin, ML; Karakula, SL; McHugh, RK; Weiss, RD, 2016) |
| "Therefore, the treatment of opioid dependence in a liver transplant recipient requires special attention in terms of graft function, drug interactions, and patient compliance." | ( Aldemir, E; Coskunol, H; Kilic, M; Sert, I, 2016) |
| "Emotion regulation among opioid misusers may represent an important treatment target." | ( Bryan, CJ; Froeliger, B; Garland, EL; Howard, MO; Nakamura, Y, 2017) |
| "Among women without opioid use disorder (and therefore not exposed to opioid maintenance therapy), delayed villous maturation was identified in 5." | ( Caritis, SN; Catov, JM; Lemon, LS; Mokhtari, NB; Parks, WT; Serra, AE; Venkataramanan, R, 2017) |
| "Buprenorphine is commonly used to treat opioid use disorder; however, non-buprenorphine prescription opioid use among these patients is not well defined." | ( Alexander, GC; Daubresse, M; Pollack, HA; Saloner, B, 2017) |
| "Methadone is used to treat opioid dependence (OD), acting as a selective agonist at the μ-opioid receptor encoded by the gene OPRM1." | ( Cook-Sather, SD; Farrer, LA; Gelernter, J; Hakonarson, H; Jensen, KP; Kranzler, HR; Li, J; Nunez, Y; Smith, AH, 2017) |
| "Concomitant opioid misuse is an increasing problem in opioid maintenance treatment as it interferes with treatment success." | ( Adam, R; Al-Iassin, J; Canolli, M; Koller, G; Krause, D; Martin, G; Musselmann, R; Plörer, D; Pogarell, O; Schäfer, F; Walcher, S; Winter, C, 2017) |
| "To evaluate established opioid addiction treatment programs that use traditional healing in combination with buprenorphine-naloxone maintenance treatment in 6 First Nations communities in the Sioux Lookout region of northwestern Ontario." | ( Cirone, S; Edwards, C; Folk, D; Gordon, J; Kahan, M; Kanate, D; Kelly, L; Kirlew, M; Main, F; Mamakwa, S; Parsons, P; Rea, S, 2017) |
| "Over 300,000 patients with an opioid use disorder (OUD) receive methadone maintenance therapy from opioid treatment programs (OTPs) in the United States." | ( Benoit, E; Dunlap, E; Elliott, L; Matusow, H; Rosenblum, A, 2018) |
| "The multi-site Prescription Opioid Addiction Treatment Study (POATS), conducted by the National Drug Abuse Treatment Clinical Trials Network, was the largest clinical trial yet conducted with patients dependent upon prescription opioids (N=653)." | ( Rao, V; Weiss, RD, 2017) |
| "Buprenorphine-naloxone treatment for opioid use disorder has rapidly expanded, yet little is known about treatment outcomes among patients in the general population." | ( Caleb Alexander, G; Daubresse, M; Saloner, B, 2017) |
| "Options for treatment of opioid dependence, acute pain management, and perioperative multimodal analgesia are discussed." | ( Pan, A; Zakowski, M, 2017) |
| "To examine relapse to opioid use disorder in a randomized, multi-site effectiveness trial of extended-release injection naltrexone (XR-NTX) vs community-based treatment as usual (TAU) without medication, as a function of the type of clinical service where treatment was initiated-short-term inpatient (N=59), long-term inpatient (N=48), or outpatient (N=201)." | ( Boney, TY; Chen, DT; Fishman, MJ; Friedmann, PD; Gordon, M; Hu, MC; Lee, JD; Nunes, EV; O'Brien, CP; Wilson, D, 2018) |
| "The majority of Americans with opioid use disorder remain out of treatment." | ( Cunningham, CO; Fox, AD; Frost, T; Lopez, C; Sohler, NL, 2017) |
| "Prescription opioid abuse treatment admissions in the 2004-2013 Treatment Episode Data Set were used to calculate counts and percentages of prescription opioid treatment admissions reporting oral, injection, or smoking/inhalation abuse overall, by sex, age, and race/ethnicity." | ( Christensen, A; Gladden, RM; Jones, CM, 2017) |
| "Pregnant women with opioid use disorder can be treated with methadone, buprenorphine, or naltrexone to reduce opioid use and improve retention to treatment." | ( Griffin, BL; Stone, RH; Todd, TJ; Tran, TH; Vest, KM, 2017) |
| "Our study of the available oral treatments for opioid dependence has revealed that no current treatment can actually claim to be fully effective." | ( Benéitez, MC; Gil-Alegre, ME, 2017) |
| "Patients with opioid use disorder often require multiple treatment attempts before achieving stable recovery." | ( Cheng, DM; Hui, D; Kim, H; Labelle, C; Quinn, E; Samet, JH; Weinstein, ZM, 2017) |
| "In France, most cases of opioid use disorder are treated with buprenorphine by general practitioners in private practice." | ( Auriacombe, M; Dupouy, J; Fatséas, M; Lapeyre-Mestre, M; Micallef, J; Oustric, S; Palmaro, A, 2017) |
| "The rate of opioid addiction, in particular, has been rising steadily in recent years, which necessitates deeper understanding of risk factors in order to develop effective prevention and treatment methods." | ( Allen, MT; Frydecka, D; Garami, J; Haber, P; Misiak, B; Moustafa, AA; Myers, CE, 2017) |
| "Despite increasing rates of opioid misuse and hospitalizations, rates of treatment for those with opioid use disorder (OUD) are very low." | ( McKenna, RM, 2017) |
| "There has been a rise in opioid abuse and related injection drug use in the United States, and treatment for opioid use disorders may be underutilized." | ( Burt, R; Glick, SN; Thiede, H; Tsui, JI, 2018) |
| "Current treatments of opioid addiction include primarily maintenance medications such as methadone." | ( Bellivier, F; Bloch, V; Jourdaine, C; Lépine, JP; Marie-Claire, C; Vorspan, F, 2017) |
| "The current understanding is that opioid misuse is a disease that requires treatment, and is not an issue of choice or character." | ( Carr, NJ; Clarke, H; Demsey, D; Vipler, S, 2017) |
| "We identified variables used to predict opioid abuse from electronic health records and administrative data." | ( Alzeer, AH; Bair, MJ; Jones, J, 2018) |
| "Risk factors for opioid misuse or addiction include past or current substance abuse, untreated psychiatric disorders, younger age, and social or family environments that encourage misuse." | ( Webster, LR, 2017) |
| "To explore potential changes in opioid misuse trends among substance-using treatment seekers, in temporal relation to legislative response." | ( Hoffman, LA; Lewis, B; Nixon, SJ, 2017) |
| "Management of patients with opioid use disorder (OUD) commonly includes opioid agonist therapy (OAT) as a part of an integrated treatment plan." | ( Alam, F; Alho, H; Auriacombe, M; Benyamina, A; Bobes, J; D'Agnone, O; Daulouede, JP; Dematteis, M; Leonardi, C; Littlewood, R; Maremmani, I; Somaini, L; Soyka, M; Szerman, N; Torrens, M; Walcher, S, 2017) |
| "The Current Opioid Misuse Measure (COMM) is a commonly used self-report instrument to identify and monitor aberrant opioid-related behavior in chronic pain patients on opioid therapy." | ( Black, RA; Butler, SF; Jamison, RN; McCaffrey, SA; Villapiano, AJ, 2019) |
| "Given the historically low rates of opioid use disorder medication adoption in treatment programs, single-state agency targeted funding is a potentially important tool to reduce mortality and morbidity associated with opioid disorders and misuse." | ( Abraham, AJ; Andrews, CM; D'Aunno, T; Friedmann, PD; Grogan, CM; Humphreys, K; Pollack, HA, 2018) |
| "Inmates with untreated opioid addiction often relapse shortly after release into the community, thereby increasing the risk of overdose, serious illnesses (HIV, hepatitis C) and psychosocial problems (e." | ( Chaplin, MM; Farahmand, P; Modesto-Lowe, V, 2017) |
| "Adults with a diagnosis of opioid dependence who initiated treatment with XR-NTX, BUP, MET, or NPT between January 1, 2011 and December 31, 2014 were identified in the Truven Health MarketScan Commercial administrative claims database." | ( Atreja, N; Duncan, M; Gore, M; Shah, A; Tai, KS, 2018) |
| "Approaches to the treatment of opioid use disorder are also subject to sex and gender differences-an area in need of further investigation." | ( Beauchamp, GA; Cannon, RD; Koons, AL; Rayl Greenberg, M, 2018) |
| "Methadone maintenance programs (MMP) for opioid dependence treatment have been widely used due to their effective therapeutic outcomes." | ( Esojo, A; Grau-López, L; Martínez-Luna, NG; Palma-Álvarez, RF; Perea, M; Robles-Martínez, M; Rodríguez-Cintas, L; Roncero, C, 2018) |
| "The federal response to the opioid use disorder crisis has included a mobilization of resources to encourage office-based pharmacotherapy with buprenorphine, an effort culminating in the 2016 Comprehensive Addiction and Recovery Act, signed into law as Public Law 114-198." | ( Goodman, D; Johnson, MC; Murphy, J; Terplan, M, 2018) |
| "Treatment for opioid use disorder involving opioid-based pharmacotherapies is considered most effective when accompanied by psychosocial interventions." | ( Agus, D; Fingerhood, MI; Krawczyk, N; Negron, T; Nieto, M, 2018) |
| "Individuals with opioid use disorder entering treatment between July 2006 and June 2015." | ( Ball, SA; Barry, DT; Eggert, KF; Farnum, SO; Freeman, RM; Madden, LM; Quanbeck, AR; Savage, ME; Schottenfeld, RS; Shi, JM, 2018) |
| "Unfortunately, treatment of opioid dependence is difficult, particularly because of codependence - for example, on alcohol or other drugs of abuse." | ( Bujalska-Zadrożny, M; de Cordé, A; Filip, M; Kleczkowska, P; Krząścik, P; Wolińska, R, 2018) |
| "Patients with opioid dependence who were prescribed XR-NTX treatment and then enrolled into the registry." | ( Akerman, SC; Liu, CC; Saxon, AJ; Silverman, BL; Sullivan, MA; Vocci, FJ, 2018) |
| "Medication treatment for opioid use disorder is effective, and recommended for adolescents, though very few adolescents with opioid use disorder ever receive medications." | ( Bromberg, J; Levy, S; Mendes, SJ; Mountain-Ray, S; Reynolds, J, 2018) |
| "Participants were recruited from an opioid dependence treatment center in an urban setting in the Southeastern United States." | ( Hicks, J; Morse, E; Wyant, DK, 2018) |
| "Women in treatment for opioid dependence both desire and attempt to establish breastfeeding, but encounter significant challenges, including long NICU stays and lack of support and education, that compromise their success." | ( Hicks, J; Morse, E; Wyant, DK, 2018) |
| "Efficacious medications to treat opioid use disorders (OUDs) have been slow to diffuse into practice, and insurance coverage limits may be one important barrier." | ( Barry, CL; Busch, AB; Huskamp, HA; Riedel, LE, 2018) |
| "Buprenorphine treatment for opioid use disorder improves HIV outcomes and other outcomes." | ( Cunningham, CO, 2018) |
| "Treating patients with opioid use disorder (OUD) and traumatic brain injury illustrates 6 neurobiological principles about the actions of 2 contrasting opioid analgesics, morphine and fentanyl, as well as pharmacotherapies for OUD, methadone, naltrexone, and buprenorphine." | ( Graham, DP; Kosten, TR; Nielsen, DA, 2018) |
| "have an opioid use disorder, less than 40% of whom receive evidence-based treatment." | ( Bohnert, ASB; Haffajee, RL; Lagisetty, PA, 2018) |
| "Treatment of opioid use disorder often begins with brief intensive inpatient or outpatient programs." | ( Abrantes, AM; Blevins, CE; Gordon, AL; Kurth, ME; Stein, MD, 2018) |
| "Buprenorphine treatment for opioid use disorder may be improved by sustained-release formulations." | ( Bailey, GL; Chen, M; Frost, M; Kampman, KM; Kim, S; Linden, M; Lofwall, MR; Nunes, EV; Oosman, S; Peterson, S; Sheldon, B; Sigmon, SC; Tiberg, F; Walsh, SL, 2018) |
| "Tertiary prevention includes treating opioid use disorders and providing naloxone to prevent overdose death." | ( Binswanger, IA; Peglow, SL, 2018) |
| "Treatment for opioid dependence in Ireland is provided predominantly by general practitioners (GP) who have undergone additional training in opioid agonist treatment (OAT) and substance misuse." | ( Crowley, D; Delargy, I; McBride, A; Van Hout, MC, 2018) |
| "Prescription opioid abuse and misuse often begins through oral administration and progresses into non-oral routes (e." | ( Nalamachu, SR; Shah, B, 2022) |
| "With the current prevalence of opioid abuse and misuse, it appears currently that mitragynine is deserving of more extensive exploration for its development or that of an analog as a medical treatment for opioid abuse." | ( Katz, JL; Kopajtic, TA; Yue, K, 2018) |
| "Patients with opioid use disorder (OUD) show memory deficiencies and impaired treatment outcomes." | ( Chang, YH; Chen, KC; Chen, PS; Chen, SH; Chen, SL; Chu, CH; Hong, JS; Huang, SY; Lee, IH; Lee, SY; Lu, RB; Tzeng, NS; Wang, TY; Yang, YK, 2018) |
| "The primary treatment for opioid use disorder (OUD) is medication assisted treatment (MAT)." | ( Brede, E; MacLean, RR; Robinson, C; Sofuoglu, M; Waters, AJ, 2018) |
| "She is in treatment for opioid use disorder on extended-release naltrexone injection, with a history of opioid overdose, relapse, and poor treatment adherence on methadone and buprenorphine." | ( Jones, CW; Terplan, M, 2018) |
| ": Medication-assisted treatment for opioid use disorder (OUD), which incorporates methadone, buprenorphine, or naltrexone, has been shown to reduce all-cause mortality rates in patients with this disease-and the numbers of patients receiving such treatment is substantial." | ( Broglio, K; Matzo, M, 2018) |
| "The treatment of pregnant women with opioid use disorder is challenging due to the myriad of physical, mental, and social complications." | ( Catlin, D; Coker, JL; Knight, B; Ray-Griffith, S; Stowe, ZN, 2018) |
| "Factors associated with prescription opioid misuse in a chronic pain treatment population are limited, and increasing our understanding of associated factors could lead to improved targeting of prevention and intervention efforts." | ( Carty, JN; Grekin, ER; Loree, AM; Lumley, MA; M Z Smith, K; Oberleitner, LMS; Valentino, D, 2019) |
| "Patients with opioid dependence who received oral tramadol treatment for a period of more than 6 months were recruited." | ( Kumar, S; Lal, R; Sarkar, S; Singh Balhara, YP; Varshney, M, 2019) |
| "Effective treatment of opioid addiction remains a big challenge today." | ( Fan, P; Ge, S; Wang, L; Wu, W; Wu, X; Xie, S; Xie, XQ, 2018) |
| "Pharmacotherapy for opioid addiction with methadone, buprenorphine, and naltrexone has proven efficacy in reducing illicit opioid use." | ( Gordon, MS; Gryczynski, J; Jaffe, JH; Kelly, SM; Mitchell, MM; Mitchell, SG; O'Grady, KE; Schwartz, RP, 2018) |
| "There is a substantive problem of opioid dependence in this difficult-to-reach population of Punjab, with low treatment access." | ( Avasthi, A; Basu, D; Gargi, PD; Ghosh, A; Goyal, BL; Gupta, PK; Sharma, A; Sidhu, BS; Subodh, BN, 2019) |
| "Among people with opioid use disorder, people with disabilities were less likely to receive treatment for prescription opioid use (Risk Ratio = 0." | ( Brucker, DL; Henly, M; Lauer, EA, 2019) |
| "Effective and widely available opioid addiction treatment resources are needed to ensure successful resolution of the "opioid epidemic"." | ( James, DL; Jowza, M, 2019) |
| "We compared opioid pain relievers and opioid addiction therapies to 5 other commonly prescribed drug types important to the Medicaid expansion population (antidepressants, antihypertensives, diabetes medications, cholesterol treatments, and contraceptives) and to overall prescription volume." | ( Cher, BAY; Meara, E; Morden, NE, 2019) |
| "Growth in prescriptions used to treat opioid use disorder greatly outpaced other drugs, suggesting important gains in access to addiction treatments; growth was higher in states with higher pre-2014 overdose death rates." | ( Cher, BAY; Meara, E; Morden, NE, 2019) |
| "Expanding treatment for opioid addiction has been recognized as an essential component of a comprehensive national response to the opioid epidemic." | ( Hockenberry, JM; Pollack, HA; Wen, H, 2018) |
| "Expanding access to treatment of opioid use disorder (OUD) is central to addressing the US overdose mortality crisis." | ( Csete, J, 2019) |
| "Providing medications for opioid use disorder (MOUD) with methadone, buprenorphine, and extended-release naltrexone is essential to achieving optimal HIV treatment outcomes including viral suppression and retention in treatment." | ( Fanucchi, L; Korthuis, PT; Springer, SA, 2019) |
| "Medications to treat opioid use disorder, including methadone and buprenorphine, are highly effective in reducing the morbidity and mortality related to illicit opioid use." | ( Bach, P; Calcaterra, SL; Chadi, A; Chadi, N; Kimmel, SD; Morford, KL; Roy, P; Samet, JH, 2019) |
| "Women with opioid use disorder who become pregnant are a particularly vulnerable population and require a comprehensive treatment approach for mother and fetus." | ( Carter, LC; Nicholas, JS; Read, L; Read, MA; Schmidt, E, 2019) |
| "Despite increasing prevalence of opioid use disorder among females, little is known about sex considerations in relation to treatment with buprenorphine." | ( Cleverley, K; Ling, S; Mangaoil, R; Puts, M; Sproule, B, 2019) |
| "In a US sample of people treated for opioid use disorder, continued treatment with either buprenorphine or methadone was associated with a reduction in arrests relative to no treatment." | ( Evans, EA; Hser, YI; Huang, D; Yoo, C; Zhu, Y, 2019) |
| "The multisite Prescription Opioid Addiction Treatment Study examined different durations of buprenorphine-naloxone treatment and different intensities of counseling to treat prescription opioid dependence, as assessed by DSM-IV; following the clinical trial, a longitudinal study was conducted from March 2009-January 2013." | ( Carroll, KM; Fitzmaurice, GM; Griffin, ML; Hilton, BT; Marcovitz, DE; McHugh, RK; Weiss, RD, 2019) |
| "Unfortunately, women with opioid use disorders often face numerous barriers when trying to access prenatal care services including limited availability or treatment options, stigma, legal consequences, co-morbid psychiatric disorders, and trauma exposure." | ( Johnson, E, 2019) |
| "Screening for opioid use disorder in the ED and initiating buprenorphine/naloxone treatment with rapid referral to an outpatient community-based addictions clinic led to a 6-month treatment retention rate of 37% and a significant reduction in ED visits at 3 and 6 months." | ( Hu, T; Nijmeh, L; Pyle, A; Snider-Adler, M, 2019) |
| "One emerging treatment strategy for opioid use disorder includes immunopharmacotherapies or opioid-targeted vaccines." | ( Banks, ML; Blake, S; Bremer, PT; Faunce, KE; Hwang, CS; Janda, KD; Natori, Y; Townsend, EA; Zhou, B, 2019) |
| "Patients with opioid use disorder (OUD) frequently present to the emergency department (ED) after overdose, or seeking treatment for general medical conditions, their addiction, withdrawal symptoms, or complications of injection drug use, such as soft tissue infections." | ( Chawarski, MC; D'Onofrio, G; Edelman, EJ; Fiellin, DA; Hawk, KF; Huntley, K; Martel, SH; Murphy, SM; O'Connor, PG; Oden, N; Owens, PH; Pantalon, MV; VanVeldhuisen, P, 2019) |
| "Untreated opioid use disorder (OUD) affects the care of HIV/HCV co-infected people who inject opioids." | ( Barocas, JA; Eftekhari Yazdi, G; Fiellin, DA; Freedberg, KA; Linas, BP; Morgan, JR; Schackman, BR; Stein, MD, 2019) |
| "Pregnant women with opioid use disorder who are stable in a medication-assisted treatment program with behavioral health can be informed that tapering or full detoxification from opioid drugs does not increase the fetal risk of poor pregnancy outcome." | ( Hennessy, M; Rackley, B; Terry, P; Towers, CV; Visconti, K, 2020) |
| "Buprenorphine, used for opioid use disorder (OUD) treatment during pregnancy, provides unknown effects on maternal physiological activity." | ( DiPietro, JA; Jansson, LM; Jones, H; McConnell, K; Milio, L; Spencer, N; Velez, ML, 2019) |
| "Persons with opioid use disorder (OUD) hospitalized with severe, injection-related infections (SIRI) are frequently hospitalized for the duration of IV antibiotic treatment due to concerns regarding their eligibility for outpatient parenteral antimicrobial therapy (OPAT), which is the standard of care for prolonged IV antibiotic courses for patients without drug use." | ( Fanucchi, LC; Lofwall, MR; Thornton, AC; Walsh, SL, 2019) |
| "Pregnant women undergoing treatment for opioid use disorder (OUD) may be exposed to multiple QT prolonging agents." | ( Bolin, EH; Coker, J; Daily, JA; Escalona-Vargas, D; Eswaran, H; Lowery, CL; Siegel, ER; Stowe, ZN, 2019) |
| "A mainstay treatment for opioid addiction in North America is methadone maintenance therapy (MMT) - a form of opiate agonist therapy (OAT)." | ( Barrett, SP; Chinneck, A; Conrod, PJ; Laroque, F; Lawrence, M; Mahu, IT; Morin, JF; Nogueira-Arjona, R; Sako, A; Stewart, SH; Swansburg, J, 2019) |
| "Most adults with opioid use disorder remain untreated, much less received outpatient treatment to address their addiction." | ( Rhee, TG; Rosenheck, RA, 2019) |
| "The mainstay of the management of opioid use disorder in pregnancy is with methadone or buprenorphine medication-assisted treatment." | ( Katz, E; Towers, CV; Visconti, K; Weitz, B, 2020) |
| "Individuals with opioid use disorders (OUD) face significant barriers to accessing medication-assisted treatment (MAT), yet access to MAT is critical to reducing opioid-related fatality." | ( Dennis, ML; Funk, RR; Grella, CE; Kurz, R; Nicholson, L; Scott, CK; Sumpter, J, 2020) |
| "Fortunately, treatment for opioid use disorders is available." | ( Betcher, HK; Croarkin, PE; Gandhi, KD; Larrabee, BR; Limbeck, MG; Romanowicz, M; Rummans, TA; Shekunov, J; Vande Voort, JL, 2019) |
| "Although they are efficacious in treating opioid dependence, buprenorphine and methadone present risks, especially during pregnancy, causing neonatal abstinence syndrome and adverse obstetrical outcomes." | ( Busardò, FP; Carlier, J; Di Trana, A; Huestis, MA; La Maida, N; Pichini, S; Tittarelli, R, 2020) |
| "Among people with opioid use disorder, initiation of, and linkage to, office-based buprenorphine treatment post-discharge reduced illicit opioid use and increased days of buprenorphine treatment for up to 6 months post-discharge compared with an in-patient detoxification protocol." | ( Anderson, B; Bailey, G; Conti, M; Herman, D; Stein, M, 2020) |
| "Fewer than 20% of Americans with opioid use disorder receive empirically-supported treatment." | ( Sigmon, SC, 2019) |
| "Medication-assisted treatment for opioid use disorder with methadone or buprenorphine may ameliorate some of this risk; however, there is presently limited research in humans, including in non-HIV populations, describing changes in immune activation on these treatments which is of paramount importance for those with HIV infection." | ( Hileman, CO; McComsey, GA, 2019) |
| "This article describes opioid use disorder in the United States, treatment gaps, safe treatment with buprenorphine, and PA prescriptive authority." | ( Fogarty, KJ; Lagerwey, MD; Radi, JK, 2019) |
| "Many patients with opioid use disorder are treated in primary care, where effective addiction treatment can be provided." | ( Coffa, D; Snyder, H, 2019) |
| "Fifteen men with opioid use disorder on methadone maintenance treatment have been enrolled from an addiction treatment center as an experimental group in this case-controlled study." | ( Hu, WL; Hung, YC; Kuo, CE; Liu, CT; Tsai, MC; Wu, SY; Wu, TC, 2019) |
| "Patients with opioid use disorder admitted to publicly funded residential treatment programs in the province of Ontario between January 1, 2013, and December 31, 2016." | ( Harrington, K; Kahan, M; Leece, P; Meaney, C; Que, B; Shehadeh, V; Spithoff, S; Sullivan, F; Urbanoski, K, 2019) |
| "Our objective was to determine how opioid use disorder treatment access impacts the relationship between adult opioid use and NAS." | ( Abbinanti, K; Krist, AH; Pecsok, J; Sabo, RT; Tong, ST; Wolf, ER; Woolf, SH, 2019) |
| "Measures of opioid use disorder treatment access dampened the correlation between illicit drug use/dependence and NAS." | ( Abbinanti, K; Krist, AH; Pecsok, J; Sabo, RT; Tong, ST; Wolf, ER; Woolf, SH, 2019) |
| "Given rising rates of opioid use disorder (OUD) and related consequences, opioid treatment programs (OTPs) can play a pivotal role in the U." | ( Byrd, DJ; Campbell, TB; Clarke, TJ; Jones, CM; McCance-Katz, EF; Ohuoha, C, 2019) |
| "Few patients with opioid use disorder receive medication for addiction treatment." | ( Barnett, ML; Frank, RG; Lee, D, 2019) |
| "Medication treatment for opioid use disorder (MOUD), methadone, buprenorphine, and naltrexone, is widely used to treat OUD in the community." | ( Brezel, ER; Fox, AD; Powell, T, 2020) |
| "Medication treatment for opioid use disorder (M-OUD) is underutilized, despite research demonstrating its effectiveness in treating opioid use disorder (OUD)." | ( Gertner, AK; Green, SL; Shea, CM, 2021) |
| "Access to adequate treatment for opioid use disorder (OUD) has been a high priority among American policymakers." | ( Brayne, C; Roman-Urrestarazu, A; Yang, JC, 2019) |
| "Treatment of opioid use disorder (OUD) with buprenorphine is a recommended part of primary care, yet little is known about current U." | ( Binswanger, IA; Bobb, JF; Boudreau, DM; Bradley, KA; Campbell, CI; Glass, JE; Johnson, EA; Lapham, G; Liu, D; Matthews, AG; McCormack, J; Murphy, MT; Rossom, RC; Samet, JH; Saxon, AJ; Yarborough, BJH, 2020) |
| "For patients who develop opioid use disorder (a chronic and relapsing problematic use of opioids that causes clinical impairment or distress), treatment combining opiate receptor full or partial agonist medications for opioid-use disorder (MOUD) with psychosocial interventions is essential." | ( Alho, H; Dematteis, M; Lembo, D; Maremmani, I; Roncero, C; Somaini, L, 2020) |
| "Simply treating opioid addiction isn't enough." | ( Archambault, C; Davis, B; Davis, K; Kennedy, A; Oagley, CR; Schneider, J; Wilensky, D, 2019) |
| "Despite its effectiveness for opiate abuse and chronic pain treatment, methadone has disruptive effects on the hypothalamic pituitary gonadal axis and sexual function." | ( Ortman, HA; Siegel, JA, 2020) |
| "Most people with alcohol or opioid use disorders (AUD or OUD) are not diagnosed or treated for these conditions in primary care." | ( Baldwin, LM; Donovan, D; Hallgren, KA; Keppel, GA; Mollis, B; Stephens, KA; Stuvek, B; West, I; Witwer, E, 2020) |
| "Hospitalizations related to opioid use disorder (OUD) are increasing, necessitating an increase in the delivery of opioid agonist therapy (OAT) among hospitalized adults." | ( Englander, H; McCarty, D; Priest, KC, 2020) |
| "The increasing prevalence of opioid use disorders among pregnant and postpartum women (PPW) has generated a need for greater availability of specialized programs offering evidence-based and comprehensive substance use disorder treatment services tailored to this population." | ( Ali, MM; Hinde, JM; Meinhofer, A, 2020) |
| "Medications for opioid use disorder (MOUD) significantly reduces the risk of overdose when compared with no treatment." | ( Champagne-Langabeer, T; Langabeer, JR; Swank, MW, 2020) |
| "Untreated opioid use disorder (OUD) complicates endocarditis management." | ( Barocas, JA; McLoone, D; Morgan, JR; Stein, MD; Wang, J; Wurcel, A, 2021) |
| "Many adults with opioid use disorder (OUD) report that their first exposure to opioids was in the course of routine pain treatment in medical care settings." | ( Dash, GF; Feldstein Ewing, SW; Hudson, KA; Murphy, C; Wilson, AC, 2020) |
| "Demand for treatments for severe opioid use disorder is increasing worldwide." | ( Fluyau, D; Pierre, CG; Revadigar, N, 2020) |
| "Medications for opioid use disorder (MOUD) and recovery homes that have traditionally served those not taking medications for their recovery are important resources for treating opioid use disorder." | ( Bobak, TJ; Hickey, P; Jason, LA; Jeong, H; Majer, JM; Norris, J, 2020) |
| "To examine associations between opioid use disorder (OUD) treatment pathways and overdose and opioid-related acute care use as proxies for OUD recurrence." | ( Ameli, O; Azocar, F; Chaisson, CE; Crown, WH; Larochelle, MR; McPheeters, JT; Sanghavi, DM; Wakeman, SE, 2020) |
| "While many individuals with opioid use disorder seek treatment at residential facilities to initiate long-term recovery, the availability and use of medications for opioid use disorder (MOUDs) in these facilities is unclear." | ( Bergeria, CL; Dunn, KE; Hobelmann, JG; Huhn, AS; Oyler, GA; Strickland, JC; Umbricht, A, 2020) |
| "Admissions for opioid use disorder at residential treatment facilities in the United States that identified opioids as the patient's primary drug of choice." | ( Bergeria, CL; Dunn, KE; Hobelmann, JG; Huhn, AS; Oyler, GA; Strickland, JC; Umbricht, A, 2020) |
| "Medications for opioid use disorder (OUD) are the most effective treatment for OUD, but uptake of these life-saving medications has been extremely limited in US prisons and jail settings, and limited data are available to guide policy decisions." | ( Adams, JW; Brinkley-Rubinstein, L; Clarke, JG; Goedel, WC; Green, TC; Macmadu, A; Marshall, BDL; Martin, RA; Rich, JD, 2020) |
| "This model, known as the Comprehensive Opioid Addiction Treatment (COAT) program, was developed in West Virginia, the epicenter of the opioid epidemic." | ( Berry, JH; Hustead, JD; Lander, LR; Mahoney, JJ; Marshalek, P; Winstanley, EL; Zheng, W, 2020) |
| "Treatment for opioid use disorders has recently evolved to include long-acting injectable and implantable formulations of medications for opioid use disorder (MOUD)." | ( Budney, AJ; Marsch, LA; Metcalf, SA; Moore, SK; Saunders, EC; Scherer, E; Walsh, O, 2020) |
| "In order to successfully treat opioid use disorder and overdose in emergency rooms, they must have waivered providers and they must be equipped with the necessary resources." | ( Fuehrlein, B; Jaeger, S, 2020) |
| "Relapse is common in treatment for opioid use disorders (OUDs)." | ( Burns, GL; McPherson, S; Tragesser, S; Vest, NA, 2020) |
| "In France, most patients with opioid use disorder (OUD) have been treated by buprenorphine, prescribed by general practitioners (GP) in private practice since 1996." | ( Dupouy, J; Lapeyre-Mestre, M; Mansiaux, Y; Maumus-Robert, S; Pariente, A, 2020) |
| "Although the treatment of opioid use disorder (OUD) is a key element in the response to the opioid overdose epidemic, currently available pharmacotherapies (e." | ( Bach, P; Brar, R; Dong, H; Fairbairn, N; Murphy, SM; Socias, ME; Wood, E, 2020) |
| "How those with opioid use disorder (OUD) navigate this inpatient treatment system after an encounter for detoxification and subsequent risk of opioid-related overdose is not well understood." | ( Babakhanlou-Chase, H; Barocas, JA; Bharel, M; Durham, NN; Jaeger, JL; Linas, BP; Morgan, JR; Walley, AY; Wang, J, 2020) |
| "As the burden of opioid use disorder (OUD) increases in the United States, manifold federal and state initiatives have sought to increase access to treatment for OUD, which includes behavioral and pharmaceutical treatment modalities." | ( Goldman, JE; Marshall, BDL; Rich, JD; Samuels, EA, 2020) |
| "Patients identified to have opioid use disorder (OUD) and willing to engage in treatment were eligible for ED-initiated buprenorphine and peer recovery coaches assisted in arranging next day follow up with a community treatment program or other local provider for ongoing treatment." | ( Barth, K; Bogan, C; Brady, K; Funcell, C; Goldsby, S; Haynes, L; Jennings, L; Lane, S; Moreland, A; Oros, M, 2020) |
| "However, because of limited access to opioid use disorder (OUD) treatment and socioeconomic factors, many pregnant (and postpartum) women with OUD do not receive treatment." | ( Berrettini, WH; Crist, RC; Doyle, GA; Reiner, BC; Weller, AE, 2021) |
| "This article focuses on screening for opioid misuse, selecting appropriate treatment for patients, initiating medication-assisted treatment in the inpatient setting, and providing appropriate peripartum care." | ( Bouchard, L; Cheng, C; Zhao, L, 2020) |
| "Medications for opioid use disorder (MOUD) demonstrate the best evidence for treating OUD." | ( Altice, FL; Bromberg, DJ; Nyhan, K; Refsland, BM; Stanojlović, M; Viera, A; Whittaker, S, 2020) |
| "New treatments to combat opiate addiction are sorely needed." | ( Blair, G; Davis, JM; Ko, A; Levin, ED; Modarres, J; Pace, C; Rezvani, AH; Rose, JE; Wells, C, 2020) |
| "The rising prevalence of opioid use disorder (OUD) and related complications in North America coupled with limited numbers of specialists in addiction medicine has led to large gaps in treatment." | ( Bhatraju, EP; Donroe, JH; Edelman, EJ; Tsui, JI, 2020) |
| "Hospitalization of patients with opioid use disorder (OUD) is increasing, yet little is known about opioid agonist therapy (OAT: methadone and buprenorphine) administration during admission." | ( Englander, H; Lovejoy, TI; McCarty, D; Priest, KC; Shull, S, 2020) |
| "Adolescents with opioid use disorder are less likely than adults to receive medications for opioid use disorder (MOUD), yet we know little about facilities that provide addiction treatment for adolescents." | ( Alinsky, RH; Cerda, M; Hadland, SE; Matson, PA; Saloner, B, 2020) |
| "XR-NTX treatment in smokers with opioid use disorder was associated with a 29% decline in daily cigarette consumption." | ( Elman, I; Langleben, DD; Shi, Z; Wang, AL, 2020) |
| "Treatment of opioid use disorder (OUD) with buprenorphine decreases opioid use and prevents morbidity and mortality." | ( Chawarski, MC; Coupet, E; Cowan, E; Curry, L; D'Onofrio, G; Edelman, EJ; Fiellin, DA; Hawk, KF; Lyons, MS; Martel, SH; O'Connor, PG; Owens, PH; Pantalon, M; Richardson, L; Rothman, RE; Whiteside, LK, 2020) |
| "We hereby report the first case of opioid dependence who developed a rare phenomenon of moderate to severe opioid withdrawal symptoms on administration of sublingual BNX after several days of being stabilized on plain buprenorphine (BUP)." | ( Bhatia, G; Sarkar, S, 2020) |
| "A major problem in treating opioid use disorder remains the high rate of relapse." | ( Eitan, S; Madison, CA; Wellman, PJ, 2020) |
| "Evidence-based outpatient treatment for opioid use disorder (OUD) consists of medications that treat OUD (MOUD) and psychosocial treatments (e." | ( Busch, AB; Greenfield, SF; Huskamp, HA; Normand, ST; Reif, S, 2020) |
| "To advocate for the extension of Opioid Use Disorder (OUD) treatment and harm minimisation services in South Africa, better estimates of the extent of opioid use is needed." | ( Dada, S; Harker, N; Laubscher, R; Lucas, WC; Myers, B; Parry, CD, 2020) |
| "Medication-assisted treatment (MAT) for opioid use disorder (OUD) is accessed half as often in rural versus urban areas in the United States." | ( Cox, KJ; Haozous, EA; Hayes, L; Scorsone, KL, 2020) |
| "Medications for opioid use disorder (MOUD), such as methadone and buprenorphine, are effective strategies for treatment of opioid use disorder (OUD) and reducing overdose risk." | ( Bruneau, J; Cochran, G; Cox, N; Gordon, AJ, 2020) |
| "Individuals with opioid use disorder may be at heightened risk of opioid overdose during the COVID-19 period of social isolation, economic distress, and disrupted treatment services delivery." | ( Bush, HM; Quesinberry, D; Rock, P; Slavova, S; Walsh, SL, 2020) |
| "Office-based buprenorphine treatment of opioid use disorder (OUD) does not typically include in-person directly observed therapy (DOT), potentially leading to non-adherence." | ( Kim, TW; Klein, JW; Leroux, BG; Radick, AC; Samet, JH; Saxon, AJ; Schramm, ZA; Tsui, JI; Ventura, AS, 2020) |
| "Although treatment of opioid use disorders (OUD) with medications is expanding, the extent to which practitioners are prescribing medications following best practices has received little attention." | ( Hinde, JM; Kluckman, M; Mark, TL; Parish, W; Zarkin, GA, 2020) |
| "Most people with opioid use disorder (OUD) are not treated with FDA-approved medications methadone, buprenorphine, or naltrexone." | ( Bachhuber, MA; Barry, CL; Kennedy-Hendricks, A; McGinty, EE; Stone, E, 2020) |
| "The risk of opioid use disorder among patients with sickle cell disease who are treated with chronic opioids remains unclear, but the complications associated with opioid use and overdose can be accentuated in those with sickle cell disease." | ( Beauchamp, G; Cannon, RD; Cook, MD; Haggerty, AG; Katz, KD; Koons, A, 2020) |
| "Some opioid use disorder (OUD) patients attempt to self-treat using herbal remedies such as kratom." | ( Douglas, HE; Weiss, ST, 2021) |
| "Many people being treated for opioid use disorder continue to use drugs during treatment." | ( Bertz, JW; Burgess-Hull, AJ; Epstein, DH; Kowalczyk, WJ; Panlilio, LV; Phillips, KA; Preston, KL; Stull, SW, 2020) |
| "Patients with opioid use disorder (OUD) frequently present to the emergency department for acute treatment of overdose and withdrawal." | ( Calleo, VJ; Sullivan, RW; Szczesniak, LM, 2020) |
| "Medication-assisted treatment (MAT) for opioid use disorder with buprenorphine in primary care is effective and patient-accessible yet remains underutilized, including among residency training programs." | ( Tiemstra, JD; Walsh, LH, 2020) |
| "A multigravid woman with opioid use disorder presented at 7 weeks of gestation for treatment." | ( Field, TA; Saia, K; Wanar, A, 2020) |
| "Not all people experiencing opioid dependence benefit from oral opioid agonist treatment." | ( Ali, R; Belackova, V; Bell, J; Bruno, R; Day, C; Degenhardt, L; Dietze, P; Farrell, M; Grebely, J; Lancaster, K; Larance, B; Lintzeris, N; Nielsen, S; Sanfilippo, P; Silins, E, 2021) |
| "Women with opioid use disorder (OUD) face unique challenges the moment they enter treatment." | ( Dunn, KE; Huhn, AS, 2020) |
| "Evidence-based treatment of opioid use disorder, the prevention of opioid overdose and other opioid-related harms, and safe and effective pain management are priorities for the Veterans Health Administration (VHA)." | ( Bohnert, ASB; Drexler, K; Frank, JW; McGuire, M; Sandbrink, F, 2020) |
| "Looking forward, to address both opioid use disorder and COVID-19, jails and prisons need to develop capacity to implement mitigation strategies, including universal and rapid COVID-19 testing of staff and incarcerated individuals, and be resourced to provide evidence-based addiction treatment." | ( Donelan, CJ; Evans, EA; Hayes, E; Potee, RA; Schwartz, L, 2021) |
| "The Prescription Opioid Misuse and Abuse Questionnaire had excellent test-retest reliability; the percentage agreement between the two Prescription Opioid Misuse and Abuse Questionnaire administrations was high (>90%) for most questions." | ( Barsdorf, AI; Bukhari, AA; Butler, SF; Coyne, KS; Currie, BM; Farrar, JT; Fisher, HJ; Mazière, JY; Pierson, RF; Schnoll, SH, 2021) |
| "Medications used to treat opioid use disorder can potentially impact dissociative symptoms, but the existing literature has not explored this." | ( Crawford, TN; Fischer, KB; Gainer, DM; Wright, MD, 2021) |
| "With expanded understanding of opioid use disorder, withdrawal, and available treatments, emergency nurses will be better prepared to deliver and support life-saving treatments for patients and families suffering from this disease." | ( Baumann, MR; Strout, TD; Wendell, LT, 2021) |
| "For people with opioid use disorder hospitalized with endocarditis or osteomyelitis, initiation of methadone or buprenorphine appears to be associated with improved receipt of gold-standard therapy, as quantified by increased days on intravenous antibiotic treatment." | ( Alvarez, C; Bartholomew, TS; Cordova, L; Jo, Y; Nosal, R; Tookes, HE; Vandever, C; Vittori, A, 2021) |
| "Access to medications for opioid use disorder (MOUD) is essential, but patients face many barriers when pursuing treatment and MOUD." | ( Ball, J; Colvard, MD; Dadiomov, D; Hill, LG; Nichols, SD; Peckham, AM; Tallian, K; Tran, TH; Ventricelli, DJ, 2021) |
| "Morbidity and mortality from opioid use disorders (OUD) and other substance use disorders (SUD) is a major public health crisis, yet there are few medications to treat them." | ( John Rush, A; Volkow, ND; Wang, Q; Xu, R; Zheng, C; Zhou, M, 2021) |
| "Treatment with medications for opioid use disorder (MOUD) can significantly reduce overdose risk, but no national studies to date have reported on the extent to which AI/ANs access these treatments overall and in relation to other groups." | ( Ahmad, NJ; Garrett, B; Krawczyk, N; Patel, E; Saloner, B; Solomon, K; Stuart, EA, 2021) |
| "Most people with opioid use disorder (OUD) never receive treatment." | ( Addis, M; Altschuler, A; Arnsten, J; Bart, G; Bobb, JF; Borst, DT; Boudreau, DM; Braciszewski, JM; Bradley, KA; Caldeiro, RM; Campbell, CI; Glass, JE; LaBelle, CT; Lapham, GT; Lee, AK; Liebschutz, JM; Liu, DS; Matthews, AG; McCormack, J; McNeely, J; Merrill, JO; Murphy, SM; Samet, JH; Saxon, AJ; Schwartz, RP; Stotts, AL; Szapocznik, J; Tsui, JI; Wartko, PD; Weinstein, ZM; Yarborough, BJH, 2021) |
| "Guidelines for treatment of opioid use disorder stipulate for mental health assessment and the option for treatment alongside medication for opioid use disorder (MOUD)." | ( Pollini, RA; Snell-Rood, C; Willging, C, 2021) |
| "(1) Background: Opioid use disorder (OUD) is a complex condition that can require long-term treatment." | ( Benoit Hardouin, J; Challet-Bouju, G; Dany, A; Grall-Bronnec, M; Guillou-Landreat, M; Laforgue, E; Leboucher, J; Victorri-Vigneau, C, 2021) |
| "The treatment capacity for opioid use disorder (OUD) lags far behind the number of patients in need of treatment." | ( Dela Cruz, AM; Pipes, R; Trivedi, MH; Wakhlu, S; Walker, R, 2021) |
| "Access to treatment for opioid use disorder (OUD) is poor." | ( Bates, AE; Martin-Misener, R, 2022) |
| "Patients with opioid use disorder (n = 14) on opioid maintenance treatment with a lasting wish for abstinence, who failed to reach abstinence with standard care." | ( Belgers, M; Donders, R; Knuijver, T; Kramers, K; Schellekens, A; van Oosteren, T; Verkes, R, 2022) |
| "Effective treatments for opioid use disorder exist, but rural areas of the United States have a shortage of services offering such treatments." | ( Dhanani, LY; Franz, B; Miller, WC, 2021) |
| "Persons with opioid use disorder (OUD) and co-occurring alcohol use disorder (AUD) are understudied and undertreated." | ( Bhat, NR; Bierut, LJ; Borodovsky, JT; Grucza, RA; Mintz, CM; Presnall, N; Xu, KY, 2021) |
| "Many persons with opioid use disorder (OUD) initiate medication for opioid use disorder (MOUD) with one clinic and switch to another clinic during their course of treatment." | ( Chang, CH; Cochran, G; Cole, ES; DiDomenico, E; Donohue, JM; Drake, C; Gellad, WF; Gordon, AJ; Kelley, D; Kim, JY; Kmiec, J; Nagy, D; Pringle, J; Sharbaugh, M; Warwick, J, 2021) |
| "Many incarcerated individuals with opioid use disorder remain untreated due to inadequate access to opioid agonist therapy (OAT)." | ( Bozinoff, N; Marmel, A, 2020) |
| "Access to treatment for opioid use disorder (OUD) in rural areas within the United States remains a challenge." | ( Cole, ES; DiDomenico, E; Green, S; Heil, SKR; Hilliard, T; Mossburg, SE; Salvador, JG; Sussman, AL; Warwick, J; Westfall, JM; Zittleman, L, 2021) |
| "Although opioid use disorder (OUD) is common in patients with cirrhosis, it is unclear how medication treatment for OUD (MOUD) is used in this population." | ( Agbalajobi, O; Belperio, P; Fine, MJ; Gellad, W; Good, CB; Kraemer, K; Morgan, T; Rogal, S; Youk, A; Zhang, H, 2021) |
| "For those on medication to treat opioid use disorder (MOUD), incarceration in either setting may disrupt treatment." | ( Bart, G; Cook, R; Giang, LM; Hoffman, K; King, C; Korthuis, PT; Waddell, EN, 2022) |
| "Patient-reported outcomes in the treatment of opioid dependence may differ between subcutaneously administered depot buprenorphine and daily sublingual buprenorphine." | ( Arunogiri, S; Dunlop, AJ; Graham, R; Haber, PS; Hayes, V; Hjelmström, P; Hutchinson, S; Lintzeris, N; Lubman, DI; Peterson, S; Svedberg, A; Tiberg, F, 2021) |
| "Retaining people with opioid use disorder in treatment longer can increase these benefits." | ( Ching, JH; Goldhaber-Fiebert, JD; Owens, DK; Salomon, JA; Trafton, JA, 2021) |
| "For people with opioid use disorder who are not responding to oral opioid agonist treatment, evidence supports the effectiveness of injectable opioid agonist treatment with injectable hydromorphone (an opioid analgesic) and diacetylmorphine (pharmaceutical grade heroin)." | ( Jun, J; MacDonald, S; Oviedo-Joekes, E; Palis, H, 2021) |
| "While opioid use disorder (OUD) is prevalent, little is known about what patients with OUD in sustained remission think about the chronic disease model of OUD and their perspectives of the cause, course, and ongoing treatment needs of their OUD." | ( Carrese, J; Chander, G; Gunn, C; Pytell, JD; Rastegar, DA; Sklar, MD, 2022) |
| "To assess differences in the quality of opioid use disorder (OUD) treatment received by Medicare beneficiaries enrolled in health plans that used prior authorization (PA) for buprenorphine-naloxone compared with those enrolled in plans that did not use PA." | ( Mark, TL; Parish, WJ; Weber, E; Zarkin, GA, 2022) |
| "Availability of medications for opioid use disorder (MOUD) has increased during the past two decades but treatment retention and adherence remain low." | ( Dunphy, C; Jones, CM; Peterson, C; Zhang, K, 2021) |
| "Medications for opioid use disorder (OUD) are the gold standard for treating OUD and preventing overdose but are underused among people with OUD, with disproportionately low treatment initiation and retention among people of color." | ( Andraka-Christou, B, 2021) |
| "Adults with opioid use disorder recruited from 8 community treatment programs across the United States." | ( Campbell, ANC; Choo, TH; Fishman, M; Greiner, MG; Lee, JD; Novo, P; Nunes, EV; Pavlicova, M; Rotrosen, J; Scodes, J; Shulman, M, 2021) |
| "Medications for opioid use disorder, including methadone, combined with comprehensive wraparound services, are the gold standard for treatment in pregnancy." | ( Abatemarco, DJ; Barber, C; Baxter, JK; Cruz, Y; Hand, DJ; Roman, AR; Rosenthal, EW; Short, VL, 2021) |
| "Compared with opioid use disorder, methamphetamine use is a public health crisis that has limited evidence-based pharmacologic interventions for long-term treatment." | ( Kremer, M; Schulkin, J; Wakeman, B, 2021) |
| "Among adults with comorbid opioid use disorder and mental disorders, treatment with buprenorphine-naloxone produced greater reductions in opioid use than treatment with methadone." | ( Evans, EA; Fei, Z; Hser, YI; Kelleghan, A; Matthews, A; Mooney, LJ; Saxon, AJ; Yoo, C; Zhu, Y, 2022) |
| "Medication for opioid use disorder (MOUD) is associated with substantial reductions in the risk of mortality, and American and Canadian guidelines recommend it as part of the full range of available treatments for youth with opioid use disorder (OUD)." | ( Davison, C; Krebs, E; McGowan, G; Min, JE; Nosyk, B; Zhou, H, 2021) |
| "Strategies for treating opioid use disorder can be divided into those that target the opioid receptor system and those that target non-opioid receptor systems, including the dopamine and glutamate receptor systems." | ( Cao, DN; Li, F; Li, J; Wu, N, 2023) |
| "Successful treatment of patients with opioid use disorder may lay in rebuilding social networks." | ( Alexander, M; Funaro, MC; Howell, BA; Janmohamed, K; Kumar, N; Lee, ST; O'Connor, PG; Oles, W, 2021) |
| "Usual treatment for persons with opioid use disorders who are in prison is detoxification with referral to treatment after release but failure to engage in treatment and relapse is common." | ( Carroll, J; Lynch, KG; Poole, S; Woody, GE; Yu, E, 2021) |
| "Medications for opioid use disorder (MOUD) are highly effective, but barriers along the cascade of care for opioid use disorder (OUD) from diagnosis to treatment limit their reach." | ( Chaisson, CE; Ciemins, E; Larochelle, MR; Morgan, JR; Quinn, EK; Stempniewicz, N; White, LF, 2022) |
| "Treatment for opioid use disorder (OUD) may include a combination of pharmacotherapies (such as buprenorphine) with counseling services if clinically indicated." | ( Arndt, S; Carnahan, RM; Charlton, M; Field, RW; Lund, BC; Vakkalanka, JP; Ward, MM, 2022) |
| "Among patients with opioid use disorder admitted to inpatient treatment, homelessness, parole and probation status, medication preference, and factors likely to influence tolerability of medication initiation may be important in matching patients to buprenorphine or extended-release naltrexone." | ( Campbell, ANC; Lee, JD; Novo, P; Nunes, EV; Pavlicova, M; Rotrosen, J; Scodes, JM, 2021) |
| "Persons with opioid use disorder should initiate BUP to not only treat substance use but also to increase viral suppression allowing for treatment as prevention." | ( Chander, G; Fojo, AT; Keruly, JC; Kim, J; Lau, B; Lesko, CR; Moore, RD, 2021) |
| "The treatment of opioid use disorder with buprenorphine and methadone reduces morbidity and mortality in patients with opioid use disorder." | ( D'Onofrio, G; Hawk, K; Hoppe, J; Ketcham, E; LaPietra, A; Moulin, A; Nelson, L; Schwarz, E; Shahid, S; Stader, D; Wilson, MP, 2021) |
| "Efforts to increase opioid use disorder (OUD) treatment have focused on primary care." | ( Alexander, GC; Foti, K; Heyward, J; Jones, C; Kolodny, A; Meek, K; Tajanlangit, M, 2021) |
| "Pharmacological treatments for opioid use disorders (OUDs) may have mixed efficacy across diverse groups, i." | ( Nalven, T; Schick, MR; Spillane, NS; Weyandt, LL, 2021) |
| "Buprenorphine, a medication for opioid use disorder (OUD), can be administered within primary care; however, little is known about characteristics associated with retention on buprenorphine in these settings." | ( Angier, H; Bailey, SR; Cantone, RE; Cohen, DJ; Fleishman, J; Garvey, B; Gordon, L; Lucas, JA; Rdesinski, RE, 2021) |
| "Among persons with opioid dependence, persons with co-occurring alcohol dependence were 25 % less likely to receive medication treatment relative to those without AUD." | ( Bierut, LJ; Grucza, RA; Hartz, SM; Mintz, CM; Presnall, NJ; Sahrmann, JM; Xu, KY, 2021) |
| "In response to a high burden of opioid use disorder (OUD), Iran established a network of opioid agonist treatment (OAT) centres beginning in 2002." | ( Bastani, P; Charkhgard, N; Conigrave, KM; Kebriaeezadeh, A; Mirrahimi, B; Narenjiha, H; Noroozi, A; Salehi, M; Vaziri, A, 2022) |
| "In light of its potential relevance for opioid abuse and potential impact on conservative management strategies, clinicians are advised to screen for perceived injustice in patients with pain following cancer treatment." | ( Beckwee, D; Bults, R; De Couck, M; Huysmans, E; Lahousse, A; Leysen, L; Mostaqim, K; Nijs, J; Reynebeau, I; Roose, E; van Wilgen, P, 2021) |
| "Medications for opioid use disorder, also known as medication-assisted treatment (MAT), are critical in the treatment of opioid use disorder." | ( Binder, R; McNiel, DE; Schonfeld, A; Toyoshima, T, 2021) |
| "Outcomes included identification of opioid use disorder, buprenorphine administration, and linkage to outpatient addiction treatment." | ( Campbell, A; Clayton, S; Goodman-Meza, D; Herring, AA; Kalmin, MM; Moulin, A; Padwa, H; Shoptaw, S; Snyder, H; Speener, M, 2021) |
| "Medication treatment of opioid use disorder (MOUD) is effective, yet barriers to care continue to result in a large proportion of untreated individuals." | ( Aryal, A; Barreveld, AM; Chhay, S; Dopp, A; Emerick, T; Kohan, L; Lane, O; Potru, S; Sprintz, M; Viscusi, E, 2021) |
| "Treatment of opioid use disorder (OUD) in adolescents and young adults is imperative to reduce the risk of overdose and other opioid-related harms." | ( Dennis, ML; Funk, R; Godley, MD; Mataczynski, MJ; Welsh, JW, 2022) |
| "Buprenorphine treatment for opioid use disorder (OUD) has positive outcomes including reducing opioid-related morbidity and mortality." | ( Boley, RA; Hill, K; Karnik, NS; Salisbury-Afshar, E; Smithenry, D, 2022) |
| "Buprenorphine, approved for treating opioid use disorder (OUD), is not equally efficacious for all patients." | ( Crist, RC; Edelman, EJ; Hartwell, EE; Kampman, KM; Kember, RL; Kranzler, HR; Rentsch, CT; Vickers-Smith, R; Xu, H, 2021) |
| "Preferences for medication for opioid use disorder (MOUD) formulation and OUD treatment models were assessed through an online survey." | ( Budney, AJ; Cavazos-Rehg, P; Marsch, LA; Saunders, EC; Scherer, E, 2021) |
| "Relapse rates during opioid use disorder (OUD) treatment remain unacceptably high." | ( Díaz, I; Luo, SX; Nunes, EV; Rotrosen, J; Rudolph, KE, 2021) |
| "Medications for opioid use disorder (MOUD), such as buprenorphine and methadone, are effective in reducing the significant harms associated with untreated opioid use disorder (OUD) in nonpregnant and pregnant adults." | ( Aujla, R; Boyars, L; Cleary, E; Douglas, E; Guille, C; Smith, C; Sujan, A, 2022) |
| "Medications for opioid use disorder (MOUD) are evidence-based treatments, yet can be controversial among some populations." | ( Light, T; Madden, EF; Prevedel, S; Sulzer, SH, 2021) |
| "Medication for opioid use disorder, including buprenorphine and methadone, is considered the gold standard treatment for opioid use disorder (OUD)." | ( Dougherty, J; Englander, H; Herreid-O'Neill, A; Lovejoy, TI; Mackey, K; Priest, KC; Shull, S; Thoma, J; Wyse, JJ, 2022) |
| "Individuals treated for opioid use disorder (OUD) have high rates of psychiatric disorders potentially diminishing treatment outcomes." | ( Curtis, ME; Evans, EA; Hser, YI; Kelleghan, A; Mooney, LJ; Saxon, AJ; Yoo, C; Zhu, Y, 2021) |
| "The stigma in treating opioid addiction continues to be a major barrier to effective management plan." | ( Dirani, E; Laqueille, X; Lucet, C; Richa, S, 2022) |
| "Access to treatment for opioid use disorder is more robust in urban areas compared with rural areas." | ( Barnett, ML; Humphreys, K; Kiang, MV; Tsai, AC; Wakeman, SE, 2021) |
| "Treating acute pain among persons with opioid use disorder (OUD) on opioid agonist therapy (OAT) is complex, and the therapeutic benefits of opioids remain unclear when weighted against their abuse potential and respiratory depressant effects." | ( Avila-Quintero, VJ; Compton, P; De Aquino, JP; Flores, J; Gómez, O; Hickey, T; Parida, S; Sofuoglu, M, 2021) |
| "As part of a broader study of opioid misuse, we examined proximity to evidence-based treatment as a potential barrier to treatment access." | ( Bowles, JM; Davidson, PJ; Faul, M; Gaines, TL, 2022) |
| "Pharmacotherapy for opioid use disorder is effective but underused from a clinical perspective, and average treatment duration is shorter than current recommendations." | ( McPheeters, J; Mutter, R; Spencer, D, 2022) |
| "Medications for opioid use disorder such as opioid agonist treatment (OAT, including methadone, buprenorphine) are the gold standard intervention for opioid use disorder (OUD)." | ( Arias, F; Arnsten, J; Cunningham, CO; Olsen, JP; Rivera Mindt, M; Scott, TM, 2021) |
| "Pharmacological treatments for opioid use disorder are essential, life-saving medications, yet successful induction of them and long-term retention on them is limited in many settings." | ( Dale, LM; Kurz, M; Min, JE; Nosyk, B, 2022) |
| "The majority of individuals with opioid use disorder (OUD) face access barriers to evidence-based treatment, and the COVID-19 pandemic has exacerbated the United States (US) opioid overdose crisis." | ( Aronowitz, SV; Dolan, A; Engel-Rebitzer, E; Lowenstein, M; Mandell, D; Meisel, Z; Oyekanmi, K; South, E, 2021) |
| "Most people receiving medications for opioid use disorder reported taking methadone and had high continuity of treatment (86." | ( Allen, ST; Haney, K; Krawczyk, N; Morris, M; Saloner, B; Sherman, SG; Solomon, K, 2022) |
| "Individuals in treatment for opioid use disorder (OUD) have high smoking rates and limited success with Food and Drug Administration (FDA)-approved cessation aids, suggesting need for novel approaches." | ( Bearnot, B; Coker, FK; Gupta, PS; Kalagher, KM; Kalkhoran, S; Neil, J; Park, ER; Regan, S; Rigotti, NA; Streck, JM; Wakeman, S, 2022) |
| "Individuals in treatment for opioid use disorder (OUD) have high smoking rates and limited success with existing smoking cessation tools, suggesting a need for novel cessation treatment approaches." | ( Bearnot, B; Coker, FK; Gupta, PS; Kalagher, KM; Kalkhoran, S; Neil, J; Park, ER; Regan, S; Rigotti, NA; Streck, JM; Wakeman, S, 2022) |
| "We know little about what youth with opioid use disorders (OUD) think about outpatient substance use treatment and 12-step meetings following discharge from residential substance use treatment." | ( Fishman, M; Lertch, E; Ludwig, A; Mitchell, SG; Monico, LB; Schwartz, RP, 2022) |
| "The mainstay of treatment for opioid use disorder (OUD) is opioid agonist therapy (OAT), which modulates opioid receptors to reduce substance craving and use." | ( Fuehrlein, BS; Gold, MS; Lee, YK, 2022) |
| "In the United States, methadone for opioid use disorder (OUD) is limited to highly regulated opioid treatment programs (OTPs), rendering it inaccessible to many patients." | ( Farrell, NM; Kehoe, J; Kolodziej, J; Komaromy, M; Laks, J; Taylor, JL; Walley, AY, 2021) |
| "Data from Phase 2 of the Prescription Opioid Addiction Treatment Study (POATS) were used." | ( Edwards, KA; McHugh, RK; Venner, KL; Vowles, KE; Witkiewitz, K, 2022) |
| "Mothers who screen positive for opioid abuse should be referred to a provider experienced in opioid maintenance therapy." | ( Schroeder, M; White, J, 2021) |
| "To address the critical need for opioid use disorder (OUD) treatment by rapidly planning and implementing a statewide DEA X-waiver training initiative expanding office-based OUD treatment in Texas by: (1) facilitating access to buprenorphine waiver trainings to targeted regions and health care providers across the state; and (2) supporting completion of DEA X-waiver requirements." | ( Finley, EP; King, VL; Lanham, HJ; Potter, JS; Rosen, KD; Schmidt, S; Schneegans, S, 2022) |
| "Due to the ongoing opioid use disorder crisis, improved access to opioid treatment programs (OTPs) is needed." | ( Harle, CA; Jackson, JR; Menachemi, N; Silverman, R; Simon, K, 2022) |
| "Medication for opioid use disorder (MOUD) is regarded as effective in treating OUD; however, retention in MOUD programs remains low nationally." | ( Anvari, MS; Belcher, AM; Bradley, VD; Felton, JW; Kleinman, MB; Magidson, JF; Massey, EC, 2022) |
| "Although medications to treat opioid use disorder (MOUD) are the standard of care during pregnancy, there are many potential gaps in the cascade of care for pregnant people experiencing incarceration." | ( Alexander, J; Amos, E; Edwards, J; Horne, T; Jones, HE; Knittel, AK; Lin, FC; Swartzwelder, RA; Thorp, J; Tsujimoto, THM; Zarnick, S, 2022) |
| "Medications to treat opioid use disorder (OUD) including buprenorphine products are evidence-based and cost-effective tools for combating the opioid crisis." | ( Aldridge, AP; Conway, KP; Hilscher, R; Khoury, D; Parker, SJ; Zarkin, GA, 2022) |
| "More recent advances in treating opioid use disorder have changed the goals of opioid withdrawal management to achievement of abstinence from all opioids to facilitation of long-term treatment with medications for opioid use disorder." | ( Manu, P; Rogozea, LM; Shulman, M, 2022) |
| "Successful treatment of opioid misuse among people with chronic pain has proven elusive." | ( Baker, AK; Barrett, JW; Donaldson, GW; Froeliger, B; Garland, EL; Hanley, AW; Nakamura, Y; Reese, SE; Riquino, MR, 2022) |
| "The overall odds ratio for reduction in opioid misuse through the 9-month follow-up period in the MORE group compared with the supportive psychotherapy group was 2." | ( Baker, AK; Barrett, JW; Donaldson, GW; Froeliger, B; Garland, EL; Hanley, AW; Nakamura, Y; Reese, SE; Riquino, MR, 2022) |
| "Medication treatment for opioid use disorder (OUD) (MOUD; buprenorphine and methadone) reduces opioid use and overdose." | ( Biondi, BE; Schlossberg, EF; Shaw, A; Springer, SA; Vander Wyk, B, 2022) |
| "However, given the high prevalence of opioid use disorder among beneficiaries in the program, findings highlighted considerable opportunity for improvement in treatment utilization and retention and a need for increased naloxone dispensing." | ( Austin, AE; Naumann, RB; Roberts, AW; Wang, L, 2022) |
| "Medication for Opioid Use Disorder (MOUD) has been shown to decrease mortality, reduce overdoses, and increase treatment retention for patients with opioid use disorder (OUD) and has become the state-of-the-art treatment strategy in the emergency department (ED)." | ( Gothard, D; Jouriles, N; McKinnon, J; Reuter, QR; Santos, AD; Seaberg, D, 2022) |
| "Buprenorphine treatment for opioid use disorder provided in the emergency department with subsequent buprenorphine treatment by community prescribers is associated with improved outcomes, but the frequency with which this occurs is unknown." | ( Gordon, AJ; Kerber, R; Saloner, B; Sorbero, M; Stein, BD, 2022) |
| "In individuals with opioid use disorder (OUD) we assumed that 80% of SSP clients had recently injected drugs and that treatment within SSPs would have similar or improved retention compared with standard-of-care buprenorphine programs, but higher rates of active opioid use while in treatment." | ( Adams, JW; Barocas, JA; Behrends, CN; Chatterjee, A; Fox, A; Linas, BP; Madushani, RWMA; Savinkina, A; Walley, AY; Wang, J, 2022) |
| "Medication for opioid use disorder (MOUD) is the criterion standard treatment for opioid use disorder (OUD), but nationally representative studies of MOUD use in the US are lacking." | ( Annunziato, EM; Gutkind, S; Mauro, PM; Samples, H, 2022) |
| "Medications to treat opioid use disorder (MOUD) during pregnancy and in the postpartum period remain underutilized." | ( Bernstein, J; Gray, JR; Greenfield, SF; Hoeppner, BB; Jones, HE; Kelly, JF; MacMillan, KDL; Muftu, S; Partridge, S; Schiff, DM; Terplan, M; Wilens, TE; Work, EC, 2022) |
| "Medications used to treat opioid use disorders were a substantial driver of NAS, although NAS associated with these medications has declined over time." | ( Cumming, CN; Kelty, EA; Preen, DB, 2022) |
| "Medication treatment for opioid use disorder (MOUD) is an effective evidence-based therapy for decreasing opioid-related adverse outcomes." | ( Bush, K; Charron, E; Cucciare, MA; Gordon, AJ; Hayes, CJ; Hudson, TJ; Lo-Ciganic, W; Martin, BC; Yu, H, 2022) |
| "In addition, if there is an underlying opioid use disorder, efforts should be made to refer to specialised addictions care and initiate opioid agonist therapy when appropriate." | ( Juurlink, DN; Wu, PE, 2022) |
| "People with opioid use disorder (OUD) experience lower quality of life (QoL) than the general population, but buprenorphine treatment for OUD could help improve QoL of individuals with OUD." | ( Andraka-Christou, B; Entress, R; Fortson, K; Golan, M; Golan, OK; Perry, E; Pigott, T; Rivera-Atilano, R; Totaram, R; Whitaker, D, 2022) |
| "Perinatal opioid use disorder (OUD) is associated with maternal and neonatal morbidity, and treatment has been definitively shown to improve outcomes for both." | ( Kane, C; Topmiller, M, 2022) |
| "Medication for Opioid Use Disorder (MOUD) with FDA-approved methadone or buprenorphine has been shown to increase treatment retention, reduce opioid use and associated health and societal harms, and reduce opioid related overdose, and as such is considered the most effective treatment for OUD." | ( Curtin, KM; Hudnall, M; Lewis, D; Mitchell, P; Parton, J; Price, A; Samsel, S; Tramp, R; Turner, D, 2022) |
| "Most studies focused on treatment of opioid use disorder among youth, with few studies focused on early or experimental stages of opioid use." | ( Audet, M; Conrod, P; Fast, D; Hawke, LD; Henderson, J; Isaacs, JY; Khan, F; Knight, R; Lam, A; Nairn, SA; Saah, R; Stewart, SH, 2022) |
| "Many people manage their opioid use disorder (OUD) with medication-assisted treatment (MAT)." | ( Broughton-Miller, KD; Urquhart, GE, 2022) |
| "Initiating medication for opioid use disorder (MOUD) during emergency department (ED) visits is an important innovation to engage individuals in addiction treatment." | ( Adger, H; Alinsky, RH; McGinty, EE; Silva, C, 2022) |
| "Methadone for opioid use disorder (OUD) treatment is restricted to licensed opioid treatment programs (OTPs) with substantial barriers to entry." | ( Christine, PJ; Evans, J; Farrell, NM; Kehoe, J; Kim, TW; Laks, J; Taylor, JL; Walley, AY; Weinstein, ZM; White, CS, 2022) |
| "As EDs continue to care for those with opioid use disorder (OUD), clinicians should be aware of how to prevent and treat BPOW." | ( Koyfman, A; Long, B; Perrone, J; Spadaro, A, 2022) |
| "Treatment for opioid use disorder (OUD), particularly medication for OUD, is highly effective; however, retention in OUD treatment is a significant challenge." | ( Jalali, MS; Lich, KH; Marrero, WJ; Naumann, RB; Stafford, C; Wakeman, S, 2022) |
| "Among people with an opioid use disorder in the United States, only 10% receive buprenorphine treatment." | ( Bluthenthal, RN; Kral, AH; LaKosky, P; Lambdin, BH; Morris, T; Tookes, HE; Wenger, L, 2022) |
| "Opioid misuse and opioid use disorder (OUD) are important comorbidities in people with advanced cancer and cancer-related pain, but there is a lack of consensus on treatment." | ( Arnold, R; Bulls, H; Dao, E; Fitzgerald Jones, K; Kapo, J; Khodyakov, D; Liebschutz, J; Meier, D; Merlin, J; Paice, J; Ritchie, C, 2022) |
| "Medication for opioid use disorder is the evidence-based, standard of care for treating OUD in outpatient settings, especially buprenorphine because it is effective and has low toxicity." | ( Aspero, H; Bao, Y; Bogner, HR; Calderbank, T; Campbell, K; Coviello, D; Dooley, P; French, R; Harris, RA; Lowenstein, M; Maginnis, J; Mandell, DS; O'Donnell, N, 2022) |
| "As Medicaid is the largest payer for opioid use disorder (OUD) treatment services in the United States, information about Medicaid provider reimbursement is critical, and Medicaid payment policies influence the structure of OUD treatment services for everyone with OUD treatment needs." | ( Aarons, J; Clemans-Cope, L; Lynch, V; Payton, M, 2022) |
| "Mortality from opioid use disorder (OUD) can be reduced for patients who receive opioid agonist treatment (OAT)." | ( Gottlieb, DJ; Hoyt, JE; Peltzman, T; Riblet, NB; Shiner, B; Teja, N; Watts, BV, 2023) |
| "Surveys assessed demographics, opioid misuse, depression and anxiety symptoms, trauma history and symptoms, social support, and barriers to retention in treatment (e." | ( Agius, E; Broman, M; Brown, S; Kollin, R; Lee, G; Lister, JJ; Pasman, E; Resko, SM, 2022) |
| "Most people with co-occurring opioid use disorder (OUD) and mental illness do not receive effective medications for treating OUD." | ( Bromley, E; Hunter, SB; Leamon, I; Martinez, J; McCreary, M; Montero, A; Ober, AJ; Sheehe, J; Shih, KJ; Tarn, DM; Watkins, KE, 2023) |
| "Buprenorphine induction for treating opioid use disorder is being implemented in emergency care." | ( Azar, P; Greenwald, MK; Herring, AA; Nelson, LS; Perrone, J, 2022) |
| "To examine trends in opioid use disorder treatment including buprenorphine possession, urine drug testing, and opioid treatment program services during the COVID-19 public health emergency." | ( Beemon, D; Burns, M; Dague, L; Saloner, B; Tilhou, AS, 2022) |
| "Medications for opioid use disorder (MOUD), including buprenorphine, represent an evidence-based treatment that supports long-term recovery and reduces risk of overdose death." | ( Burnett, SJ; Clemency, BM; Hoopsick, RA; Kahn, LS; Lynch, JJ, 2022) |
| "Methadone treatment (MT) for opioid use disorder is only available in opioid treatment programs (OTPs) in the United States, with retention predictive of positive health outcomes." | ( Andraka-Christou, B; Nguyen, TD; Totaram, R, 2022) |
| "Minorities with opioid use disorder utilize healthcare the least, possibly because of affordability, and need culturally sensitive and financially feasible treatment options." | ( Chang, J; Kim, SJ; Medina, M, 2022) |
| "Universal screening for opioid use disorder (OUD) is recommended in pregnancy, and prevention and treatment programs that meet the specific needs of women are important to understand and consider as the world continues to try to anticipate and respond to the realities of the opioid epidemic." | ( Cook, JL, 2022) |
| "Clinicians should screen regularly for opioid use disorder and arrange for or directly provide treatment." | ( Coffin, PO; Martinez, RS; Ryder, B; Wylie, B, 2022) |
| "Stigmatization of an opioid addiction acts as a barrier to those seeking substance use treatment." | ( Ahluwalia, J; Chavanne, D; Goodyear, K, 2022) |
| "In a group of 162 patients with opioid dependence, discontinuation prior to the full 24 weeks of the study period (six injections and attending the study visit at 24 weeks) occurred in 49% of the patients, primarily in the early stage of treatment." | ( Clausen, T; Karlsson, AT; Solli, KK; Tanum, L; Vederhus, JK; Weimand, B, 2022) |
| "Young adults with opioid use disorder (OUD) have low engagement in treatment with medication for opioid use disorder (MOUD)." | ( Bagley, SM; Barron, K; dellaBitta, V; Hadland, SE; Lunze, K; Park, TW; Schoenberger, SF, 2023) |
| "Many patients with opioid use disorders do not receive evidence-based treatment." | ( Frank, CJ; Lin, LA, 2022) |
| "Treatment of opiate addiction with opiate substitution treatment (e." | ( Barker, D; Cro, S; Lingford-Hughes, AR; Mozgunov, P; Nahar, L; Paterson, LM; Paterson, S; Phillips, R; Smith, C, 2022) |
| "Partial opioid agonist medications for opioid use disorder reduce mortality and morbidity, however long-term retention in treatment is challenging." | ( Beaudoin, FL; Bratberg, J; Chambers, LC; Hallowell, BD; McDonald, J; Nitenson, A; Onyejekwe, C; Samuels, EA, 2022) |
| "The use of digital interventions for opioid use disorder treatment was acceptable, with varying levels of effectiveness for improving outcomes, which is influenced by participant and intervention delivery factors." | ( Chiliza, B; Kiburi, SK; Ngarachu, E; Paruk, S; Tomita, A, 2023) |
| "Persons with opioid use disorder (OUD) may present with infectious complications from injection drug use; thus, infectious diseases (ID) physicians are uniquely positioned to treat OUD." | ( Carter, AE; Colasanti, JA; Cooper, H; Fujita, AW; Hussen, SA; Loughry, N; Moore, DE; Sheth, AN, 2023) |
| "Persons with opioid use disorder (OUD) may present with infectious complications from injection drug use; thus, infectious diseases (ID) physicians are uniquely positioned to treat OUD." | ( Carter, AE; Colasanti, JA; Cooper, H; Fujita, AW; Hussen, SA; Loughry, N; Moore, DE; Sheth, AN, 2023) |
| "Persons with opioid use disorder (OUD) may present with infectious complications from injection drug use; thus, infectious diseases (ID) physicians are uniquely positioned to treat OUD." | ( Carter, AE; Colasanti, JA; Cooper, H; Fujita, AW; Hussen, SA; Loughry, N; Moore, DE; Sheth, AN, 2023) |
| "Medications for opioid use disorder (MOUD) are a commonly used evidence-based approach to treating affected individuals, but little is known about its use in the rural US." | ( Bresett, JW; Kruse-Diehr, AJ, 2023) |
| "Medications for opioid use disorder (MOUD) are a commonly used evidence-based approach to treating affected individuals, but little is known about its use in the rural US." | ( Bresett, JW; Kruse-Diehr, AJ, 2023) |
| "Medications for opioid use disorder (MOUD) are a commonly used evidence-based approach to treating affected individuals, but little is known about its use in the rural US." | ( Bresett, JW; Kruse-Diehr, AJ, 2023) |
| "Novel treatments for opioid use disorder (OUD) are needed to address both the ongoing opioid epidemic and long-standing barriers to existing OUD treatments that target the endogenous μ-opioid receptor (MOR) system." | ( Bergeria, CL; Bogenschutz, MP; Brown, RT; Comer, SD; Dunn, KE; Dworkin, RH; Finan, PH; Griffiths, RR; Hendricks, PS; Houtsmuller, EJ; Huhn, AS; Johnson, MW; Kampman, KM; Kiluk, BD; Kleykamp, BA; Kosten, TR; Lee, DC; Levin, FR; McRae-Clark, A; Pravetoni, M; Preston, KL; Raison, CL; Rasmussen, K; Strain, EC; Turk, DC; Vandrey, R; Weiss, RD, 2023) |
| "Novel treatments for opioid use disorder (OUD) are needed to address both the ongoing opioid epidemic and long-standing barriers to existing OUD treatments that target the endogenous μ-opioid receptor (MOR) system." | ( Bergeria, CL; Bogenschutz, MP; Brown, RT; Comer, SD; Dunn, KE; Dworkin, RH; Finan, PH; Griffiths, RR; Hendricks, PS; Houtsmuller, EJ; Huhn, AS; Johnson, MW; Kampman, KM; Kiluk, BD; Kleykamp, BA; Kosten, TR; Lee, DC; Levin, FR; McRae-Clark, A; Pravetoni, M; Preston, KL; Raison, CL; Rasmussen, K; Strain, EC; Turk, DC; Vandrey, R; Weiss, RD, 2023) |
| "Increasing access to opioid use disorder (OUD) treatment is critical to curbing the opioid epidemic, particularly for rural residents who experience numerous health and health care disparities, including higher overdose death rates and limited OUD treatment access compared with urban dwellers." | ( Caiola, C; Scott, ES; Speight, C; Tyndall, DE, 2023) |
| "Increasing access to opioid use disorder (OUD) treatment is critical to curbing the opioid epidemic, particularly for rural residents who experience numerous health and health care disparities, including higher overdose death rates and limited OUD treatment access compared with urban dwellers." | ( Caiola, C; Scott, ES; Speight, C; Tyndall, DE, 2023) |
| "Medication for opioid use disorder (MOUD) includes administering medications such as buprenorphine or methadone, often with mental health services." | ( Dekeseredy, P; Haggerty, T; Sedney, CL; Turiano, NA; Turner, T, 2022) |
| "Medication for opioid use disorder (MOUD) includes administering medications such as buprenorphine or methadone, often with mental health services." | ( Dekeseredy, P; Haggerty, T; Sedney, CL; Turiano, NA; Turner, T, 2022) |
| "Research suggests that Medication for Opioid Use Disorder (MOUD) is effective in the treatment of OUD." | ( Call, G; Dras, M; Eijaz, AA; Lim, D; Marashi, A; Pradhan, P; Siddiqui, A; Warren, D, 2022) |
| "Research suggests that Medication for Opioid Use Disorder (MOUD) is effective in the treatment of OUD." | ( Call, G; Dras, M; Eijaz, AA; Lim, D; Marashi, A; Pradhan, P; Siddiqui, A; Warren, D, 2022) |
| "Patients with opioid use disorder (OUD) tend to get assigned to one of 3 medications based on the treatment program to which the patient presents (e." | ( Díaz, I; Luo, SX; Nunes, EV; Rotrosen, J; Rudolph, KE; Williams, NT, 2023) |
| "We will enroll 100 participants with opioid use disorders receiving methadone maintenance treatment at an addiction treatment center and randomly allocate them to an experimental or control group." | ( Hu, WL; Hung, YC; Kuo, CE; Lu, TC; Tsai, MC; Tsai, YH; Wu, SY, 2022) |
| "While opioid addiction, treatment, and recovery are receiving attention, not much has been done on adaptive interventions to prevent opioid use disorder (OUD)." | ( Singh, N; Varshney, U, 2023) |
| "Medication for opioid use disorder (MOUD) is the gold standard treatment for opioid use disorder." | ( Ciocco, F; Cox, AL; Hass, RW; Kelly, EL; Reed, MK; Smith, KR; Weinstein, LC, 2023) |
| "Medications for opioid use disorder (MOUDs) - including methadone, buprenorphine, and naltrexone - are the most effective treatments for opioid use disorder (OUD)." | ( Andraka-Christou, B; Golan, O; Gordon, AJ; Ohama, M; Saloner, B; Stein, BD; Totaram, R, 2023) |
| "Pharmacy-based Opioid Use Disorder (OUD) treatment has been identified as a central pillar in curbing the spiraling opioid epidemic that claimed more than 100,000 lives in the United States in a one year period for the first time." | ( Watanabe, JH, 2023) |
| "Buprenorphine has been approved for opioid use disorder treatment, yet remains underutilized." | ( Desai, S; Guy, GP; Strahan, AE; Zhang, K, 2023) |
| "Medications used to treat opioid use disorder (OUD) reduce drug overdose risk." | ( Abate, MA; Dai, Z; Kraner, JC; Limen, GN; Mock, AR; Smith, GS, 2023) |
| "Access to medications for opioid use disorder (MOUD) is limited for individuals in drug courts - programs that leverage sanctions for mandatory substance use treatment." | ( Boland, AK; Friedmann, PD; Lemon, SC; Pivovarova, E; Smelson, DA; Taxman, FS, 2023) |
| "Patients with opioid use disorder were offered treatment with buprenorphine, a buprenorphine prescription whenever possible, and a follow-up visit to a clinic providing addiction treatment." | ( Castillo, EM; Childers, R; Cronin, AO; Lasoff, D; Swee, S, 2023) |
| "Patients with opioid use disorder (OUD) frequently leave the hospital as patient directed discharges (PDDs) because of untreated withdrawal and pain." | ( Caputo, A; Christopher, C; Compton, P; Delgado, MK; Lowenstein, M; McFadden, R; Olenik, JM; Perrone, J; Ronning, K; Sigueza, AL; Thakrar, AP; Uritsky, TJ; Winston, A, 2023) |
| "Patients with opioid use disorder may be asked by their clinicians to discontinue maintenance buprenorphine treatment before surgical operations due to concerns that buprenorphine will interfere with acute pain management." | ( Bhat, JA; Hathaway, DB; Rodriguez, C; Suzuki, J; Twark, C, 2023) |
| "Despite efficacy of medication for opioid use disorder, low-income, ethno-racial minoritized populations often experience poor opioid use disorder treatment outcomes." | ( Anvari, MS; Belcher, AM; Bennett, M; Bradley, VD; Dean, D; Felton, JW; Greenblatt, AD; Kleinman, MB; Magidson, JF; Seitz-Brown, CJ, 2023) |
| "Improving medication for opioid use disorder outcomes is a national priority that must be met with cost-effective, sustainable strategies to support individuals in treatment." | ( Anvari, MS; Belcher, AM; Bennett, M; Bradley, VD; Dean, D; Felton, JW; Greenblatt, AD; Kleinman, MB; Magidson, JF; Seitz-Brown, CJ, 2023) |
| "Among patients with opioid use disorder seeking medication treatment, the risk of overdose events over the next 24 weeks is elevated among those who fail to initiate or discontinue medication and those who report benzodiazepine use at baseline." | ( Balise, RR; Brandt, L; Castillo, F; Feaster, DJ; Hu, MC; Liu, Y; Luo, SX; Nunes, EV; Odom, GJ, 2023) |
| "Increasing evidence-based treatment for opioid use disorder (OUD) is key to reducing opioid-related morbidity and mortality." | ( Paquette, CE; Pollini, RA; Slocum, S, 2023) |
| "With increasing prevalence of opioid use disorders (OUDs) there is an urgent need for OUD trained front line primary care providers (PCPs) who can help improve patient adherence to addiction treatment." | ( Boltri, JM; Caron, A; Delos Reyes, C; Gardner-Buckshaw, SL; Khaira, P; Kropp, D; Novak, L; Perzynski, AT; Spieth, R, 2023) |
| "Regarding opioid use disorder treatment, participants supported ED-based buprenorphine/naloxone programs but also suggested additional options (eg, different initiation regimens and settings and other opioid agonist therapies) to facilitate further treatment uptake." | ( Barbic, S; Bath, M; Buxton, JA; Dong, K; Galarneau, LR; Garrod, E; Grier, S; Hilburt, J; Kaczorowski, J; Kestler, A; Miles, I; Moe, J; O'Neill, ZR; Orkin, AM; Scheuermeyer, FX; Tobin, D, 2023) |
| "Nearly 27 million people have an opioid use disorder (OUD) according to the 2016 Global Burden of Disease study, most of which occur in the US where opioids are a common class of medication used to treat acute and chronic pain." | ( Cornett, EM; Dies, RM; Edinoff, AN; Honore, LG; Jackson, ED; Kataria, S; Kaye, AD; Kaye, AM; Murnane, KS; Sall, S; Shekoohi, S; Zaheri, AR, 2023) |
| "People with Opioid Use Disorder (PWOUD) represent an underserved and marginalized population for whom treatment gaps exist." | ( Bhatt, S; Dixon, JA; Fernandez-Mancha, R; Fiuty, P; Gadomski, R; Gross, J; Salvador, J; Shapiro, M, 2023) |
| "Medication for opioid use disorder (MOUD) is evidence-based treatment during pregnancy and postpartum." | ( Ahrens, KA; Austin, AE; Chen, Q; Donohue, JM; Durrance, CP; Hammerslag, L; Jarlenski, M; Lanier, P; McDuffie, MJ; Talbert, J, 2023) |
| "Treatment for opioid use disorder (OUD) with diacetylmorphine is an evidence-based form of drug treatment, but it is not available in the United States (US)." | ( Allen, ST; Morris, M; Owczarzak, J; Rouhani, S; Schneider, KE; Sherman, SG; White, RH, 2023) |
| "Methadone medication treatment for opioid use disorder appears to remain an effective intervention for reducing illicit opioid use." | ( Dawson, E; Gordon, AJ; Passik, S; Saloner, B; Stein, BD; Whitley, P, 2023) |
| "Patients with opioid use disorder, regardless of treatment with methadone, buprenorphine, or no medication for opioid use disorder consumed significantly greater quantities of opioids after cesarean delivery but received fewer opioid prescriptions at discharge." | ( Achu, R; Bateman, BT; Gibbs, L; Guang, Z; Holland, E; Saia, K; Spence, NZ; Wachman, EM; Werler, MM; Young, M, 2023) |
| "Patients receiving medications for opioid use disorder (MOUD) depend on receiving daily treatment and face a risk of withdrawal in case of medication supply disruption." | ( Dumchev, K; Gvozdetska, O; Ivanchuk, I; Kuzin, I; Morozova, O; Nesterova, O; Skala, P, 2023) |
| "Medications for opioid use disorder (MOUD; methadone, buprenorphine, naltrexone) are the most effective treatments for OUD, and MOUD is protective against fatal overdoses." | ( Case, P; Green, TC; Hughto, JMW; Moyo, P; Palacios, WR; Rapisarda, SS; Silcox, J; Stopka, TJ; Tapper, A, 2023) |
| "Screening for opioid misuse and treatment for opioid use disorder are critical for reducing morbidity and mortality." | ( Cox, S; DeSisto, CL; Green, JL; Kacha-Ochana, A; Ko, JY; Mueller, T; Terplan, M, 2023) |
| "Hospitalized patients with opioid use disorder and concurrent acute pain may be eligible for buprenorphine therapy." | ( Chenoweth, J; Colby, D; Johnson, E; Kotova, M; Porras, H, 2023) |
| "Medication for opioid use disorder (MOUD) is an effective intervention to combat opioid use disorder and overdose, yet there is limited understanding of engagement in treatment over time in the community, contextualized by ongoing substance use." | ( Astemborski, J; Cepeda, JA; Genberg, BL; Kirk, GD; Mehta, SH; Rudolph, JE, 2023) |
| "Medications for opioid use disorder (MOUD) are the standard of care for treating opioid use disorder (OUD), but few problem-solving court clients with OUD are referred to MOUD." | ( Andraka-Christou, B; Asi, YM; Matusow, H; Totaram, R, 2023) |
| "Adults with opioid dependence entering 8 treatment centers in Tehran, Iran will be randomly assigned to receive either OMT plus a smartphone intervention or OMT as usual." | ( Boumparis, N; Meyer, A; Naghizadeh, E; Noroozi, A; Rahimi-Movaghar, A; Schaub, MP; Wenger, A, 2023) |
| "Despite a high prevalence of opioid use disorder (OUD) among people in prison, there is little knowledge of how many receive the recommended opioid agonist treatment (OAT) and what characterizes those who receive OAT and those who do not when it comes to mental health comorbidities." | ( Bukten, A; Skjærvø, I; Stavseth, MR, 2023) |
| "Medication for opioid use disorder (MOUD) in primary care includes a combination of medication, behavioral therapy, and/or other psychosocial services." | ( Gaiser, MG; Galloway, E; Lombardi, B; Richman, EL; Sullivan, C; Zerden, LS, 2023) |
| "In treating opioid use disorder (OUD), subcutaneous (SC) extended-release buprenorphine (BPN) depots, e." | ( Acharya, C; Björnsson, M; Strandgården, K; Tiberg, F, 2023) |
| "As telehealth models for treatment of opioid use disorder (OUD) are expanding, the field does not know the reliability of urine drug screening (UDS) in this setting." | ( Brandon, AD; Burke, B; Carter, R; Clear, B; Gallogly, W; Rollston, R; Weiner, SG, 2023) |
| "Medication for opioid use disorder (MOUD) with buprenorphine in primary care is a proven OUD treatment strategy." | ( Carroll, JK; Dickinson, LM; Felzien, M; Fernald, DH; Heeren, L; Kwan, BM; Lutgen, C; Nease, DE; Sofie, B; Westfall, JM; Wolff, D; Zittleman, L, 2023) |
| "Buprenorphine treatment for opioid use disorder (OUD) has more than doubled since 2009." | ( Beaudoin, FL; Berk, J; Chambers, LC; Gaither, R; Hallowell, BD; Hampson, AJ; Paiva, TJ; Wightman, RS; Zullo, AR, 2023) |
| "In this 3-arm cluster-RCT of opioid use disorders treatment programs, we test the effect of two evidence-based "practice coaching" (PC) interventions on the provision and sustained implementation of on-site HIV testing, on-site HIV/HCV testing, and linkage to care." | ( Annane, D; Assoumou, SA; Feaster, DJ; Frimpong, JA; Gooden, LK; Haynes, L; Kyle, T; Liguori, TK; Linas, BP; Matheson, T; Metsch, LR; Nelson, MC; Parish, CL; Siegel, K; Toussaint, O; Tross, S, 2023) |
| "Expansion of opioid use disorder treatment is needed, particularly in rural communities." | ( Badger, GJ; Batchelder, SR; Heil, SH; Higgins, ST; Peck, KR; Sigmon, SC, 2023) |
| "Participants were adults with untreated opioid use disorder from nonrural (trial 1) or rural (trial 2) communities." | ( Badger, GJ; Batchelder, SR; Heil, SH; Higgins, ST; Peck, KR; Sigmon, SC, 2023) |
| "Expanding access to opioid use disorder (OUD) treatment, including methadone, is imperative to address the US overdose crisis." | ( Castellanos, S; Joshi, N; Knight, KR; Lambdin, BH; Shapiro, B; Steiger, S; Suen, LW, 2023) |
| "Medication for opioid use disorder (MOUD) is an effective, evidence-based treatment, but significant gaps in implementation remain." | ( Beehler, GP; Funderburk, J; Heavey, SC, 2024) |
| "Buprenorphine treatment for opioid use disorder (OUD) is associated with decreased morbidity and mortality." | ( Christine, PJ; Larochelle, MR; Lin, LA; McBride, J; Tipirneni, R, 2023) |
| "The Primary Care Opioid Use Disorders Treatment (PROUD) trial was a mixed-methods, implementation-effectiveness cluster randomized clinical trial conducted in 6 diverse health systems across 5 US states (New York, Florida, Michigan, Texas, and Washington)." | ( Addis, M; Altschuler, A; Arnsten, JH; Bart, G; Bobb, JF; Boudreau, DM; Braciszewski, JM; Bradley, KA; Burganowski, RP; Caldeiro, RM; Campbell, CI; Cunningham, CO; Dryden, D; Ghiroli, MM; Glass, JE; Hamilton, LK; Horigian, VE; Hu, Y; Hyun, N; Idu, AE; Labelle, CT; LaHue, JS; Lapham, GT; Lee, AK; Liebschutz, JM; Liu, DS; Loree, AM; Matthews, AG; McCormack, J; McNeely, J; Merrill, JO; Murphy, MT; Murphy, SM; Northrup, TF; Phillips, RC; Qiu, H; Samet, JH; Saxon, AJ; Schwartz, RP; Shea, M; Shmueli-Blumberg, D; Silva, AJ; Stotts, AL; Szapocznik, J; Tsui, JI; Wartko, PD; Weinstein, ZM; Wong, MT; Yu, O; Zare-Mehrjerdi, M, 2023) |
| "Medication treatments for opioid use disorder (MOUD) save lives and improve outcomes for countless individuals." | ( Carr, MM; Cave, S; Martino, S; Masheb, R; Midboe, AM; Wolkowicz, NR, 2023) |
| "Medications for opioid use disorder (MOUD) are the most effective treatment for opioid use disorder (OUD) but remain underutilized." | ( Bowden, C; Crystal, S; Enich, M; Lloyd, J; Mahone, A; Treitler, P, 2024) |